

Review article: latent tuberculosis in patients with inflammatory bowel diseases receiving immunosuppression—risks, screening, diagnosis and management

Sasha R. Fehily^{1,2}  | Aysha H. Al-Ani^{2,3}  | Jonathan Abdelmalak⁴  | Clarissa Rentch³ |
 Eva Zhang³ | Justin T. Denholm^{2,5,6,7} | Douglas Johnson^{2,5} | Siew C. Ng⁸  |
 Vishal Sharma⁹  | David T. Rubin¹⁰  | Peter R. Gibson¹¹ | Britt Christensen^{2,3} 

¹Gastroenterology Department, St Vincent's Hospital, Melbourne, Victoria, Australia

²Department of Medicine, University of Melbourne, Parkville, Victoria, Australia

³Gastroenterology Department, Royal Melbourne Hospital, Parkville, Victoria, Australia

⁴Gastroenterology Department, Alfred Hospital, Melbourne, Victoria, Australia

⁵Infectious Diseases Department, Royal Melbourne Hospital, Parkville, Victoria, Australia

⁶Victorian Tuberculosis Program, Melbourne, Victoria, Australia

⁷Department of Infectious Diseases, Doherty Institute, Parkville, Victoria, Australia

⁸Department of Medicine and Therapeutics, Institute of Digestive Disease, The Chinese University of Hong Kong, Hong Kong SAR, China

⁹Department of Gastroenterology, Postgraduate Institute of Medical Education and Research, Chandigarh, India

¹⁰University of Chicago Medicine Inflammatory Bowel Disease Center, University of Chicago Medicine, Chicago, Illinois, USA

¹¹Department of Gastroenterology, Monash University and Alfred Health, Melbourne, Victoria, Australia

Correspondence

Britt Christensen, Department of Medicine, University of Melbourne, Parkville, Victoria, Australia.

Email: britt.christensen@mh.org.au

Funding information

Australian Government Research Grant, Grant/Award Number: Funding PhDs for Aysha Al-Ani and Sasha Fehily; Pfizer Foundation, Grant/Award Number: Grant to fund research and clinical fellow Eva Zhang; University of Melbourne

Summary

Background: One quarter of the world's population has latent tuberculosis infection (LTBI). Systemic immunosuppression is a risk factor for LTBI reactivation and the development of active tuberculosis. Such reactivation carries a risk of significant morbidity and mortality. Despite the increasing global incidence of inflammatory bowel disease (IBD) and the use of immune-based therapies, current guidelines on the testing and treatment of LTBI in patients with IBD are haphazard with a paucity of evidence.

Aim: To review the screening, diagnostic practices and medical management of LTBI in patients with IBD.

Methods: Published literature was reviewed, and recommendations for testing and treatment were synthesised by experts in both infectious diseases and IBD.

Results: Screening for LTBI should be performed proactively and includes assessment of risk factors, an interferon-gamma releasing assay or tuberculin skin test and

The Handling Editor for this article was Dr Mike Burkitt, and this was uncommissioned review was accepted for publication after full peer-review.

This is an open access article under the terms of the [Creative Commons Attribution-NonCommercial](https://creativecommons.org/licenses/by-nc/4.0/) License, which permits use, distribution and reproduction in any medium, provided the original work is properly cited and is not used for commercial purposes.

© 2022 The Authors. *Alimentary Pharmacology & Therapeutics* published by John Wiley & Sons Ltd.

chest X-ray. LTBI treatment in patients with IBD is scenario-dependent, related to geographical endemicity, travel and other factors. Ideally, LTBI therapy should be used prior to immune suppression but can be applied concurrently where urgent IBD medical treatment is required. Management is best directed by a multidisciplinary team involving gastroenterologists, infectious diseases specialists and pharmacists. Ongoing surveillance is recommended during therapy. Newer LTBI therapies show promise, but medication interactions need to be considered. There are major gaps in evidence, particularly with specific newer therapeutic approaches to IBD.

Conclusions: Proactive screening for LTBI is essential in patients with IBD undergoing immune-suppressing therapy and several therapeutic strategies are available. Reporting of real-world experience is essential to refining current management recommendations.

1 | INTRODUCTION

Tuberculosis (TB) is a major global health issue and communicable cause of death, accounting for 1.2 million deaths worldwide in persons not infected with the human immunodeficiency virus (HIV) in 2019.¹ After exposure to *Mycobacterium tuberculosis*, the spectrum of natural disease progression varies from immediate organism clearance to primary acute infection. In the majority of infected patients, the host immune response arrests further growth of *Mycobacterium tuberculosis* by the way of granuloma formation, leading to dormant or latent tuberculosis infection (LTBI).² Individuals with LTBI are asymptomatic of their infection but remain at risk of reactivation and development of active TB. This is estimated to occur in approximately 5%–10% of the general immunocompetent population over their lifetime.³ Importantly, LTBI is estimated to affect one quarter of the world's population.^{4,5}

Diagnosing LTBI provides a window of opportunity for treatment. Such treatment prevents reactivation and subsequent development of active TB infection, which carries a risk of significant morbidity and mortality.⁶ Guidelines recommend screening for and treating LTBI in patients at high risk of reactivation or with a high likelihood of LTBI on the basis of epidemiological risk factors.^{7,8} Treatment prevents the transmission of infection and is an essential component of eliminating TB in low-incidence countries.⁹ Key determinants to accessing available regimens are geographic location and cost.⁹

A principal risk factor for TB reactivation in those with LTBI is immune suppression or immune incompetence, with the latter including primary immune-deficiency diseases and secondary immunodeficiency.¹⁰ Immunomodulation in patients with IBD is multifactorial but primarily occurs as a function of a patient's medication regimen. IBD patients often require immune-suppressing therapies including corticosteroids, thiopurines, tumour necrosis factor (TNF)-antagonists, non-TNF-targeted biologics and targeted small molecule therapies. These therapies may impact immunological pathways integral to controlling anti-mycobacterial activity.¹¹ Secondly, malnutrition and disease activity are modifiable risk factors in IBD that

can result in an immune-suppressed state and increased risk of opportunistic infection.¹¹

Given such risks, it is surprising that guidelines on who and how to screen for and manage LTBI in patients with IBD are somewhat empirical. Further, there appears to be considerable heterogeneity in their implementation regarding, for example, who should be screened, the timing of its administration in relation to commencing immunosuppressive therapy and its duration and subsequent assessments are not uniform. Whether having IBD alone sufficiently warrants screening is not known, but, in clinical practice, the initiation of systemically acting immune-modulating therapies appears to be the trigger for addressing the question of LTBI. Underlying reasons for such haphazard practice include the exclusion of patients with LTBI in stringent research protocols, the genesis of most data from countries where TB is very uncommon, and the paucity of real-world data that inform clinical practice in terms of risk and clinical approach. Thus, this review presents the evidence and its gaps and develops evidence-based standards to guide the management of LTBI in IBD patients.

2 | INDICATIONS FOR SCREENING PATIENTS

A comparison of society and agency guidelines for LTBI screening is summarised in [Table 1](#). The current World Health Organisation (WHO) guidelines recommend screening patients with immunodeficiency diseases such as HIV infection, those with underlying chronic lung diseases such as silicosis, household contacts of persons infected with pulmonary TB and other high-risk population groups such as prisoners, healthcare workers, homeless people, people who inject drugs (PWIDs) and immigrants from high-prevalence countries. Screening is also recommended prior to the commencement of immunosuppressive therapy such as tumour necrosis factor-alpha inhibitors, organ or haematological transplantation, or renal replacement therapy.⁹ The national position statement for the management of LTBI in Australia mirrors these recommendations.^{12,13}

TABLE 1 Comparison of guidelines addressing issues in screening, diagnosis and timing of therapy for latent tuberculous infection

Issue	European Crohn's colitis organisation (ECCO) ¹¹	British Society of Gastroenterology (BSG) ⁵⁸	British Thoracic Society (BTS) ³⁸	Anters for disease control and prevention (CDC) ⁹⁸	World Health Organisation (WHO) ⁸	Australian Department of Health guidelines ¹³
When to screen	If close contact or from an endemic country Consider at diagnosis Always perform prior to anti-TNF therapy	If close contact or from an endemic country Prior to commencing anti-TNF therapy or other biological therapy	If close contact or from an endemic country Prior to anti-TNF treatment, tofacitinib, vedolizumab and ustekinumab	If close contact or from an endemic country People living with HIV or undergoing solid organ transplant People who work in high-risk settings, prisoners, people who use illicit drugs and healthcare workers Prior to immunosuppressive therapy (such as anti-TNF) or systemic corticosteroids ≥ 5 mg/d prednisolone	If close contact or from an endemic country People living with HIV or undergoing solid organ transplant or living with silicosis Consider prisoners, homeless people, people who use illicit drugs and healthcare workers Patients commencing anti-TNF therapy	If close contact or from an endemic country People living with HIV or undergoing solid organ transplant Australian residents working for prolonged periods in healthcare settings in a high-incidence country Patients commencing anti-TNF therapy
Diagnosis	Patient history, chest X-ray, TST and IGRA Use IGRA in BCG-vaccinated individuals	Clinical risk stratification, chest X-ray and IGRA	Clinical history, examination, chest X-ray and IGRA/TST	Clinical history, examination, chest X-ray and IGRA/TST	Clinical history, chest X-ray and TST/IGRA	Clinical history and TST/IGRA
Timing of anti-TNF and LTBI treatment	When there is latent TB and active IBD, anti-TNF therapy should be delayed for at least 3 weeks, except in cases of greater clinical urgency and with specialist advice When active TB is diagnosed, anti-TB therapy must be started and anti-TNF therapy stopped but can be resumed after 2 months if needed	Latent TB should be treated prior to commencing biologics	Chemoprophylaxis should be given before commencing anti-TNF- α treatment In the case of active TB, minimum of 2 months of full chemotherapy directed by a specialist in TB before starting anti-TNF- α treatment	Not addressed	Not addressed	Not addressed

The risk of LTBI reactivation in patients with IBD is related to patient and treatment factors. The European Crohn's and Colitis Organisation (ECCO) recommends clinicians consider screening on a case-by-case basis at the time of IBD diagnosis according to an individualised assessment.¹¹ During this assessment, patients should be asked about past TB exposure, symptoms, family history of TB and travel to endemic areas. The American College of Gastroenterology (ACG) advocates for screening consideration in patients with IBD prior to immunosuppressive therapy, if they are judged to have a high risk of previous exposure and undiagnosed LTBI.¹⁴ The high risk of previous exposure includes contacts with people known or presumed to have TB and long-term travellers to endemic countries (3–12 months) (Figure 1). Travellers particularly at risk include those who are in close contact with the local population, have occupational exposure and/or, those who are at higher risk of acquisition including children less than 5 years, people who are immunocompromised, cigarette smokers and patients with chronic kidney disease.

In patients who are at low epidemiological risk of LTBI, the anticipation of the treatment regimen is key to screening consideration. Apart from patients commencing anti-TNF therapy, the role of LTBI

screening in IBD is not well defined. Table 2 summarises the risk of TB reaction with different classes of IBD treatments and can be used to risk-stratify patients. Given that immunosuppression is associated with a reduction in the sensitivity of screening tests, the investigation should ideally occur when patients are not pharmacologically immunosuppressed to maximise diagnostic yield.^{11,15,16,17} The difficulty with IBD management, however, is that the need and urgency for escalation of therapy cannot always be anticipated. Hence, it is not unreasonable to screen all IBD patients at the commencement of immunosuppression. Where there is a need for escalation of therapy to an anti-TNF, for example, and LTBI screening has been performed distantly, it is also prudent to repeat screening if there is the possibility of new exposures/travel in the intervening period.

3 | DIAGNOSIS OF LATENT TUBERCULOSIS

A diagnosis of LTBI is based on clinical history, immunological assays and imaging (Tables 1 and 3). Firstly, patients should be




FIGURE 1 Estimated incidence rates of TB. Adapted from <https://www.who.int/publications/digital/global-tuberculosis-report-2021/tb-disease-burden/incidence> Figure 2.1.5. World Health Organisation; 2021. License: CC BY-NC-SA 3.0 IGO

TABLE 2 Immune modifying agent and risk of TB reactivation

Very low risk	Low risk	High risk
5-aminosalicylates (high-level evidence)	Thiopurines (moderate-level evidence) Methotrexate (moderate-level evidence) Vedolizumab (low-level evidence)	Anti-tumour necrosis factor (high-level evidence) High-dose corticosteroid (high-level evidence) Ustekinumab (low-level evidence) Tofacitinib (low-level evidence) Calcineurin inhibitors (moderate-level evidence)

TABLE 3 Diagnosis, indications and recommendations for LTBI treatment according to IBD therapy

Diagnosis of LTBI	<ul style="list-style-type: none"> • Use a combination of clinical, radiological and screening tests (TST and/or IGRA).^{6,9,13,18} • For indeterminate results repeat testing at 8 weeks post-disease flare or following the cessation of corticosteroids.^{23,25} • Involve infectious diseases physicians early where immunosuppressive therapy is emergent
Indications for LTBI treatment	<ul style="list-style-type: none"> • All decisions regarding LTBI treatment need to be considered in the context of the individual patient. Risks of reactivation with immunosuppressive therapy must be stratified and weighed against the risk of medication side effects, inconvenience of treatment and costs of therapy • By and large, positive test results will be associated with a recommendation to treat, but in some cases, the risk of treatment may be determined to outweigh the benefit • It is important to consider the involvement of an infectious diseases physician in decision-making regarding immunosuppressive therapies and decisions regarding LTBI or active TB infection
Considerations for treatment	<ul style="list-style-type: none"> • Severity of IBD at diagnosis • Likelihood of requiring escalation to high-risk drugs or combination therapies for IBD • Medication interactions, especially with rifampicin-containing regimens
Management according to a therapeutic agent	
5-aminosalicylates	<ul style="list-style-type: none"> • Risk of TB reactivation: very low risk • Recommendation: LTBI treatment is not indicated prior to or during treatment • Special considerations: consider potential blood dyscrasias with sulfasalazine and a consequent theoretical risk of reactivation of infection⁵³⁻⁵⁵
Corticosteroids	<ul style="list-style-type: none"> • Risk of TB reactivation: very high risk (cumulative dose dependent).^{11,59,60,61} • Recommendation: LTBI treatment is indicated in patients commencing prednisolone at a dose of ≥ 15 mg daily (or its equivalent) for a duration extending beyond 1 month. Ideally, LTBI treatment should be completed prior to corticosteroid commencement. Treatment duration is not impacted by corticosteroid therapy. • Special considerations: corticosteroids are often used in the setting of clinical urgency and, therefore, it is not always possible to complete a course of anti-tuberculosis therapy prior to corticosteroid initiation. In this setting, anti-tuberculosis therapy should be commenced prior to, or at least concomitantly, with corticosteroid initiation and continued until completion. Consider drug interactions when choosing a latent TB treatment regimen
Thiopurines and Methotrexate	<ul style="list-style-type: none"> • Risk of TB reactivation: low risk^{11,71} • Recommendation: LTBI treatment should be commenced prior to or alongside thiopurines/methotrexate. Delaying thiopurine or methotrexate therapy is not warranted. Prioritise LTBI treatment in patients on combination therapy with an anti-TNF. LTBI treatment duration is not impacted by thiopurine or methotrexate therapy. • Special considerations: caution with methotrexate and concurrent anti-mycobacterial treatment due to drug interactions and potential hepatotoxicity^{10,78,79,80,81,119}
Tumour necrosis factor inhibitors and anti-interleukin 12/13 (ustekinumab)	<ul style="list-style-type: none"> • Risk of TB reactivation: very high risk (lower risk in IL-12/23 therapy than with anti-TNF therapy^{110,111}) • Recommendation: ideally LTBI treatment should be completed prior to anti-TNF and anti-IL-12/23 commencement.^{11,14} In more urgent settings, it is recommended that anti-TNF/anti-IL-12/23 therapy should be delayed for at least 3 weeks of anti-tuberculosis treatment • Special considerations: in the setting of the imminent need for biological therapy, infectious diseases specialist consultation should be sought, but concomitant commencement of LTBI treatment and anti-TNF or anti-IL-12/23 therapy where clinically required can be considered. Anti-tuberculosis therapy should be continued until completion, and treatment duration is not impacted by anti-TNF or anti-IL-12/23 therapy
Anti-integrin (vedolizumab)	<ul style="list-style-type: none"> • Risk of TB reactivation: low risk.^{107,108} • Recommendations: LTBI treatment should be commenced prior to or alongside vedolizumab, especially in individuals using combination therapy. Treatment with vedolizumab should not be delayed in order to commence LTBI treatment
Janus kinase (JAK) inhibitors (tofacitinib)	<ul style="list-style-type: none"> • Risk of TB reactivation: very high risk • Recommendation: ideally, LTBI treatment should be completed prior to tofacitinib use. In more urgent settings, tofacitinib therapy should be delayed for at least 4 weeks of LTBI treatment with close monitoring for potential drug interactions • Special consideration: in the setting of the imminent need for tofacitinib use, infectious diseases specialist consultation should be sought, but the treatment of LTBI can be considered concurrently with tofacitinib commencement where clinically indicated. The anti-tuberculosis therapy should be continued until completion and treatment duration is not impacted by tofacitinib therapy. Consider drug interactions when choosing a latent TB treatment regimen
Calcineurin inhibitors (cyclosporine, tacrolimus)	<ul style="list-style-type: none"> • Risk of TB reactivation: very high risk • Recommendation: ideally, LTBI treatment should be completed prior to CNI use. In more urgent settings, CNI therapy should be delayed for at least 3 weeks of LTBI therapy with close monitoring for potential drug interactions • Special consideration: in the setting of the imminent need for CNI use, infectious diseases specialist consultation should be sought, but the treatment of LTBI can be considered concurrently with calcineurin inhibitors where clinically indicated. The anti-tuberculosis therapy should be continued until completion, and treatment duration is not impacted by calcineurin inhibitor therapy. Consider drug interactions when choosing a latent TB treatment regimen

screened for risk factors for past exposure including symptoms, personal history and travel history to endemic areas. LBTI is suggested by evidence of sustained immunological response to *Mycobacterium tuberculosis* antigens, by tuberculin skin test (TST) or interferon-gamma release assay (IGRA), in the absence of active TB infection either clinically or radiographically.¹⁸ Screening may vary slightly depending on whether the patient resides in TB-endemic or non-endemic areas (see Figures 1 and 2a,b).

3.1 | Testing for LTBI

There is no gold standard test for the diagnosis of LTBI; TST and IGRA each have their own advantages and disadvantages.^{6,9,12,18}

3.2 | Tuberculin skin test

This involves the intra-dermal injection of tuberculin-purified protein derivative (PPD). This induces a T-cell-mediated hypersensitivity response in patients with prior TB exposure, leading to an area of induration at the injection site within 48–72h. The diameter of the induration is then measured by a trained clinician.¹⁹ Threshold values for a positive test are based on the patient's pre-test probability of LTBI as well as their likelihood of progressing to active TB. Accepted diagnostic values are^{8,12,19}:

- ≥5 mm in children <5years old and immunosuppressed individuals (i.e. infected with HIV or on immunosuppressive therapy, including those on TNF inhibitors, chemotherapy and prednisolone >15 mg/day)




FIGURE 2 Detection of LTBI in IBD patients. (a) Detection of LTBI in non-endemic areas. (b) Detection of LTBI in endemic areas

- ≥ 5 mm but < 10 mm in patients who are likely to be infected and have a high risk of progression.
- ≥ 10 mm but < 15 mm in patients who are likely to be infected and have a low to intermediate risk of progression.
- ≥ 15 mm in patients who are unlikely to be infected.

Disadvantages to the TST method include the requirement for trained personnel to perform the test, risk of clinician subjectivity in interpreting the test and the requirement for a follow-up visit to assess the response to PPD injection. False-positive results may occur when an individual has a non-TB mycobacterial infection or has previously received vaccination with *Bacillus of Calmette and Guerin* (BCG). Conversely, false-negative results can occur in those with pharmacological immunosuppression or immunodeficiency, recent vaccination for measles, mumps and rubella (MMR) or those with recent TB exposure.¹⁹

3.3 | Interferon-gamma release assay

This involves testing a patient's blood for T-cell response with interferon-gamma release to antigens specific to *Mycobacterium tuberculosis*.^{18,20} IGRA is more expensive than TST and requires venepuncture. Two different IGRAs have been marketed: The QuantiFERON Gold (In-Tube and Gold Plus) and the T-Spot TB. The QuantiFERON tests use specialised blood collection tubes containing specific TB antigens and then measure interferon-gamma production from circulating T-lymphocytes.^{27,28} The T-Spot TB uses enzyme-linked immunoassays (ELISPOT) to count T-lymphocytes sensitised to TB antigens, producing a count of the number present in collected samples.²¹ Both tests measure T-cell sensitisation to TB antigens via interferon-gamma responses and are here considered effectively equivalent.

IGRA may return indeterminate results. This refers to a failure of the positive or negative mitogen control to elicit the expected interferon-gamma response. The two possibilities making the test uninterpretable include a strong response to the negative control or weak response to the positive control.

Having a diagnosis of IBD in itself does not appear to lead to an increased likelihood of an indeterminate result, but patients who are experiencing an IBD flare or are actively immunosuppressed (particularly with prednisolone doses equivalent to ≥ 20 mg/day) appear to be at a greater risk.²²⁻²⁴ A large study evaluating 3002 patients undergoing testing with IGRA showed indeterminate or equivocal results in 107 patients (3.6%). Indeterminate results were more likely in individuals tested prior to initiation of biological therapy compared to other groups, which may reflect concurrent immunosuppressive medication or the influence of underlying disease activity.²⁵ On repeat testing within 6 months, 52% returned negative, 13% positive, 23% equivocal and 9% indeterminate, highlighting the difficulty in interpreting these results.

There are two strategies that can be followed after an indeterminate IGRA test. First, the IGRA should be repeated once using the same test initially performed. Ideally, repeat testing should be

performed after the resolution of a disease flare and/or after corticosteroids have been ceased, and no sooner than 8 weeks after initial testing. However, high-risk patients should be referred to an infectious diseases consultant for the guidance in management. The second option is to perform a TST after an indeterminate IGRA. Although this is a valid screening method and TST is reliable following an IGRA test, it is important to note that an IGRA result is not reliable after TST as TST may 'boost' the immune response after 3 days.²⁶

3.4 | Comparison of assay performances

Studies directly comparing TST and IGRA in the same populations have failed to definitively conclude that one is superior to the other.²⁷⁻³¹ A meta-analysis including IBD patients demonstrated a moderate to strong concordance between TST and IGRA at 85% (95% confidence interval [CI] 77%–90%).³² Recommendations vary between guidelines, with older guidelines recommending the use of TST,³³⁻³⁸ while more recent guidelines endorse the use of IGRA.³⁹⁻⁴¹ The World Health Organisation recommends TST or IGRA as equivalent options, with local practical factors determining which test should be used.⁹ Some guidelines suggest both should be used to maximise diagnostic yield with acceptance of the likely higher false-positive rate.^{6,12,42,43,44,45}

3.5 | Imaging

Screening for TB also includes performing a clinical examination and chest x-ray.^{9,11,18,35} Chest X-ray has good sensitivity but poor specificity; in patients with radiological features of TB on chest X-ray chest, computed tomography can be used to delineate between active and LTBI⁴⁶ and to identify false-positive results^{47,48} (see Figure 2a). CT chest is also used as a screening tool in place of CXR in many TB-endemic countries or in cases where suspicion of LTBI is high where the risk of false-negative results is of higher concern (see below: Management of LTBI in TB-endemic countries) (see Figure 2b). The rationale for this is highlighted in a retrospective study of IBD patients in China which 28% had LTBI on CT chest with concordance between serological assay and imaging fallible.⁴⁹ Further, a recent study from India suggests that in TB-endemic areas, the high risk of TB reactivation upon commencing anti-TNF therapy can be significantly reduced with a stringent screening strategy that includes all the clinical history, TST, IGRA, CXR and CT chest.⁵⁰

4 | INDICATIONS FOR TREATMENT OF LTBI

The general indications for LTBI treatment include persons with a high risk of TB reactivation or those with a high pre-test probability with indeterminate or negative results.⁵¹ Guidelines advocate

preventative treatment in patients who require anti-TNF therapy (Tables 1 and 3). However, there is no consensus as to whether all patients diagnosed with IBD and LTBI should undergo empiric anti-mycobacterial treatment, nor is it standard clinical practice. Although immunosuppressive therapy is avoided or minimised where possible, the current treatment paradigm in IBD heavily emphasises the importance of escalating therapy to achieve early remission and long-term maintenance of remission. The individual likelihood of requiring a biological agent and/or combination therapy needs to be considered when determining whether or not to treat LTBI.

It is important to be cognizant of the nature of IBD as a progressive or relapsing condition, whereby an acute disease relapse may warrant the urgent need for escalation of management. This may include high-dose corticosteroid use. Hence, early LTBI therapy may be warranted, so as to ensure relatively urgent immunosuppression is not precluded or complicated. Additionally, such a 'pre-emptive' strategy may reduce the potential risk of commonly encountered drug interactions between anti-tuberculous and immunosuppressive therapies.

Indications for LTBI treatment are summarised in Table 3.

5 | TREATMENT OF LTBI

The drugs available for the treatment of LTBI, the recommended duration of therapy, advantages and disadvantages and side effects are shown in Table 4. Current national and international guidelines vary, and these are outlined in Table 5.

6 | MANAGEMENT OF LTBI ACCORDING TO THERAPEUTIC AGENT

The risk of TB reactivation with the various IBD immune modifying agents is summarised in Tables 2 and 3. The recommendations around LTBI treatment according to therapy are summarised in Table 3. The timing around IBD medication initiation and treatment of LTBI is summarised in Figure 3.

6.1 | 5-aminosalicylates

5-aminosalicylates (5-ASAs) and their pro-drug, sulfasalazine, are considered first-line therapies in the induction and maintenance of mildly to moderately active ulcerative colitis.⁵² Their exact mechanism of action is not clear, but is likely to be multi-modal. A key function is believed to be the local anti-inflammatory effect on the intestinal mucosa through inhibition of secretion and synthesis of pro-inflammatory cytokines, leukotrienes and prostaglandins.⁵³

Large cohort studies evaluating the safety profile of 5-ASAs do not demonstrate an increased risk of serious or opportunistic infections.⁵⁴ No association between 5-ASA use and TB reactivation has

been described. However, blood dyscrasias are recognised as idiosyncratic adverse drug reactions (ADR). These most commonly present as a mild transient leukopenia, but fatal agranulocytosis has been reported with sulfasalazine use.⁵⁵ This could speculatively lead to an increased risk of serious infections and the reactivation of opportunistic infections such as TB.⁵⁴

Given the overall absence of excess risk of TB reactivation in patients using 5-ASAs, there are no current guidelines recommending the initiation of LTBI therapy in 5-ASA users.

6.2 | Corticosteroids

Short-term corticosteroids are frequently prescribed in active IBD to reduce inflammation by way of impairing cellular immune response through multiple pathways.^{56,57} They are effective in inducing remission but are not recommended as maintenance therapy.⁵⁸

A dose-dependent relationship between the risk of TB reactivation in patients receiving corticosteroids is well established,^{59,60} but the specific threshold above which the risk of infection is notably increased remains unknown. In a large multicenter prospective evaluation of patients with Crohn's disease (CD) from the TREAT registry, the incidence of serious infections was 1.7%, with the strongest independent predictor being corticosteroid use (OR 2.21).⁶⁰ A case-control study based on a large general practice cohort that included 497 new cases of TB compared with 1977 controls reported an odds ratio of 4.3 for the diagnosis of TB in patients exposed to corticosteroids.⁵⁹ The risk was increased in current users and was greatest in patients receiving prednisolone at a dose of ≥ 15 mg daily. At a physiological dose of 7.5 mg daily, there was a trend towards increased risk, but this did not reach statistical significance. There was also no clear association with prolonged duration or cumulative dose.⁷⁰ However, a more recent evaluation of 3806 patients from the Taiwan National Health Insurance Research Database⁶¹ demonstrated that higher cumulative corticosteroid dosage was associated with an increased risk of TB reactivation. ECCO guidelines, consistent with the American Thoracic Society and the U.S. Centers for Disease Control and Prevention (CDC), recommend the treatment of LTBI in patients receiving corticosteroids at a dose equivalent to prednisolone 15 mg/day for at least 1 month.^{11,19}

Regarding the timing of treatment, it is important to note that the absolute risk of progressing to active TB even while receiving high-dose corticosteroids in the short term is low; the absolute risk of TB reactivation over 2 years of follow-up in a rheumatological cohort of patients with LTBI who were treated with oral corticosteroids for at least 4 weeks was approximately 5%.⁶² The cumulative and daily mean prednisolone doses 1 month prior to TB reactivation were 1 g and 15 mg respectively. Therefore, although infectious diseases consultation is recommended, it is reasonable that where clinical urgency dictates, anti-tuberculosis therapy be commenced concomitantly or just prior to corticosteroid initiation. Prospective evaluation to validate this strategy is desirable.

TABLE 4 Agents available for the treatment of latent tuberculosis

Drug regimen	Pharmacokinetic properties and bioavailability	Advantages	Disadvantages	Side effects	Cost	References
Six months of isoniazid monotherapy (6H ^a)	C_{max} : 1–2 h $T_{1/2}$: 0.7–4 h (faster for rapid acetylators) Bioavailability: 90% Effect of food: reduced absorption and C_{max} metabolised extensively by the liver. 5%–30% renally excreted (lower for rapid acetylators)	Long-term clinical experience	Hepatotoxicity Peripheral neuropathy (requires pyridoxine supplementation) Poor compliance Emerging resistance	Hepatotoxicity Asymptomatic elevation of serum liver enzymes ^{ba} Peripheral neuropathy (preventable with pyridoxine co-administration) Dizziness Reduced alertness, mild drowsiness Hypersensitivity reactions Seizures (infrequent)	\$	51,158,159
Four months of rifampicin monotherapy (4R)	C_{max} : 1–4 h $T_{1/2}$: 1.5–5 h Bioavailability: 90%–95% Effect of food: delayed absorption (~36%) and C_{max} (103%), particularly high fatty foods ^{b,c} Metabolised 60%–80% by liver 15%–30% renally excreted	Enhanced adherence compared to isoniazid Use in isoniazid resistance	Bodily fluid discolouration Lower risk of hepatotoxicity compared to isoniazid monotherapy Drug interactions common	Orange discolouration of urine, tears, saliva, semen, contact lenses (harmless) Cutaneous reactions Gastrointestinal intolerances Thrombocytopenia Haemolytic anaemias Renal failure Hypersensitivity reactions Flu-like symptoms with intermittent use	\$	161–165
Three months of rifampentine-isoniazid combination therapy (3HP)	Rifampentine C_{max} : 4.83–6 h $T_{1/2}$: 13 h Bioavailability: 70% Effect on food: increases AUC and C_{max} by 40%–50% 17% renally excreted	Enhanced adherence compared to isoniazid monotherapy Greater potency and longer half-life compared to rifampicin	Hypersensitivity reactions Lower risk of hepatotoxicity compared to isoniazid monotherapy Drug interactions common	As with rifampicin and isoniazid	\$\$\$	161,166,167
Four months of rifampicin-isoniazid combination therapy (3HR)		Enhanced adherence compared to isoniazid monotherapy. Used in paediatric setting	Hepatotoxicity Peripheral neuropathy (requires pyridoxine supplementation) Drug interactions common	As with rifampicin and isoniazid but combination increases the risk of hepatotoxicity compared to monotherapy	\$\$\$	161,162,168

Time to maximum concentration (C_{max}): elimination half-life ($T_{1/2}$).

^aIsoniazid (also known as isonicotinic acid hydrazide) is denoted as H in WHO and MSF guidelines.

^b10%–20% of patients in the first few months of therapy but it can occur at any time.

TABLE 5 Treatment options for latent tuberculosis as per current guidelines (adult dosing)

Drug regimen	Australian therapeutic guidelines	WHO (9)	CDC (19, 98)	NICE
Isoniazid monotherapy (6H)	✓ 10 mg/kg, up to 300mg daily for 6–9 months	✓ 5 mg/kg/day for 6 months	✓ ^σ 5 mg/kg/day, up to 300mg daily for 6–9 months OR 15 mg/kg up to 900mg twice weekly under DOT for 6–9 months	✓ 10 mg/kg up to 300 mg daily for 6 months
Rifampicin monotherapy (4R)	✓ 10 mg/kg up to 600mg daily for 4 months	✓ 10 mg/kg/day for 4 months	✓ 10 mg/kg up to 600mg daily for 4 months	✗
Rifapentine–isoniazid combination therapy (3HP)	✓ Rifapentine: Adult >50kg: 900mg weekly × 12 doses Adult ≤50kg: 750mg weekly × 12 doses Isoniazid: 15 mg/kg, up to 900mg weekly × 12 doses	✓ under DOT Rifapentine: 900mg weekly × 12 doses Isoniazid: 900mg weekly × 12 doses	✓ under DOT Rifapentine: Adult >50kg: 900mg weekly × 12 doses. Adult: 32.1–49.9 kg: 750mg weekly × 12 doses Isoniazid: 15 mg/kg, up to 900mg weekly × 12 doses	✗
Rifampicin–isoniazid combination therapy (3HR)	✓ Rifampicin: 10 mg/kg up to 600mg daily for 3 months Isoniazid: 5 mg/kg, up to 300mg daily for 3 months	✓ Rifampicin: 10 mg/kg/day for 3 months Isoniazid: 5 mg/kg/day for 3 months	✓ Rifampicin: 10 mg/kg up to 600mg daily for 3 months Isoniazid: 5 mg/kg, up to 300mg daily for 3 months	✓ Rifampicin: up to 600mg daily for 3 months if >50kg, up to 450mg if adult <50kg Isoniazid: up to 300mg daily for 3 months

✓ recommended.

DOT recommendation with directly observed therapy (DOT).

✗ Not recommended.

^σ CDC guidelines preferentially recommend short-course, rifamycin-based, 3- or 4-month latent TB infection treatment regimens over 6- or 9-month isoniazid monotherapy.




FIGURE 3 Initiation of immunosuppressive treatment with LTBI in IBD

The pharmacokinetic effects of rifampicin on corticosteroid clearance and bioavailability are important to consider. Rifampicin increases the plasma clearance of prednisolone by up to 45% and reduces the amount of drugs available to the tissues by up to 66%. Thus, doubling the prednisolone dose in order to achieve therapeutic concentrations can be considered or a rifampicin-free regimen may be offered.⁶³

6.3 | Immunomodulators

6.3.1 | Thiopurines

Thiopurines (including mercaptopurine and its pro-drug azathioprine) are purine analogues that have cytotoxic effects on dividing cells, therefore impairing adaptive immune responses.^{64,65} These

immunomodulators are frequently used as maintenance therapy for patients with moderate to severe IBD.⁶⁶ Due to their delayed onset of action and time to maximal pharmacodynamic effect, immunomodulators often require concomitant induction medication administration for the first 6–8 weeks of therapy.⁶⁷ Importantly, when considering the risk of TB reactivation, they are also often used synergistically with biological agents to increase efficacy and reduce immunogenicity.^{68,69}

In addition to their therapeutic immune-modulating effects, thiopurines induce dose-dependent myelosuppression, with an increased risk of infections.^{70,71} Thiopurines appear to particularly reduce the immune response to viruses, with their use associated with up to a fivefold increase in the risk of herpes simplex virus lesions and significant worsening of viral warts.⁷² The literature is, however, conflicting regarding the specific risk of thiopurine-associated respiratory tract infections or pulmonary infections. In a large registry, the risk of opportunistic infections with thiopurine monotherapy was lower than that of placebo.^{59,60} However, in a cohort study of 3806 Taiwanese patients, the risk of TB reactivation was increased in association with a high cumulative thiopurine dosage (50 mg/day for more than 1 year) (HR = 3.6, 95% CI: 1.7–7.3).⁶¹ The SONIC and UC-SUCCESS trials compared thiopurine therapy alone or in combination with an anti-TNF in patients with Crohn's disease and ulcerative colitis, respectively, and did not demonstrate an increased risk of opportunistic infections with combination therapy compared to monotherapy. However, these studies were limited by the exclusion of patients at high risk of infections and short follow-up periods.^{68,69} A recent systematic review comprising 40 randomised controlled trials reported that the highest risk of TB reactivation was associated with combination therapy compared to controls (OR 54; 95% CI 5.3–88) and with anti-TNF monotherapy (OR 13.3; 95% CI 3.7–100).¹⁰

Thiopurines have also demonstrated in vitro dose-dependent antibacterial activity against *M. paratuberculosis*. The capacity of the drugs to limit the growth of *M. paratuberculosis* was more pronounced with mercaptopurine than that of azathioprine, but neither agent was bactericidal.⁷³

There are no current guidelines advocating for the treatment of LTBI in patients treated with thiopurines.

6.3.2 | Methotrexate

Methotrexate is most commonly used in patients with Crohn's disease who are intolerant or refractory to thiopurines or, in CD and UC, in combination with anti-TNF agents.^{74–76} Its immunosuppressive activity results from the inhibition of nucleic acid synthesis in activated T cells.⁷⁷

An association between methotrexate and an increased risk of serious and opportunistic infections has not been consistently demonstrated in the literature. In particular, no recognised association with TB reactivation exists. However, when used in combination with anti-TNF therapy, a substantially increased risk of TB

reactivation has been reported. This risk is greater than the additive risk of both therapies.^{10,78}

There are no current guidelines detailing recommendations to treat LTBI in patients treated with methotrexate.

Both methotrexate and anti-mycobacterial therapeutic agents are associated with hepatotoxicity.^{79,80} Using these medications in combination has the potential to cause significant morbidity.⁸¹ Additionally, since rifampicin may reduce the serum concentrations of methotrexate, the use of a rifampicin-free regimen should be considered.⁸²

6.4 | Tumour necrosis factor-alpha inhibitors (anti-TNF)

Anti-TNF therapy is recommended for induction and maintenance of moderately to severely active IBD in patients who are steroid-dependent or steroid-resistant and/or refractory to immunomodulators^{68,83,84,85} and as primary induction therapy for perianal fistulizing Crohn's disease.^{86,87} TNF-dependent chemokines play a critical role in the process of granuloma formation.⁸⁸ The presence of TNF-alpha within macrophage-rich granulomas confers immunological and physical constraints on the *M. tuberculosis* infection. Thus, impairing granuloma formation with anti-TNF therapy increases susceptibility to reactivation as well as early dissemination and extra-pulmonary site involvement.^{89–91}

While individual randomised controlled trials did not recognise an increased risk of opportunistic infections with anti-TNFs, subsequent real-world use was associated with an increased incidence of active TB, including miliary TB, across North America and Europe.^{85,92,93} An increased risk of opportunistic infections, including TB, associated with anti-TNF therapy was demonstrated in large observational cohorts of patients with rheumatoid arthritis, including in countries with low TB prevalence.^{89,91,94,95} In a systematic review and meta-analysis that included 14,683 patients from 40 randomised controlled trials, there was a higher incidence of active TB in patients on anti-TNF monotherapy compared to controls (2/5769 vs 0/4673, OR 4; 95% CI 0.2–15.7). The risk was more substantial in the anti-TNF group that included patients on combination therapy (OR 24.8; 95% CI 2.4–133).¹⁰ Although there are no head-to-head trials, observational studies have not shown significant differences in the risk of TB reactivation comparing the different anti-TNF agents used in IBD.⁸⁹ Not surprisingly, concomitant prednisolone is a consistent predictor of TB reactivation.⁹⁶

Several guidelines recommend completing treatment of LTBI prior to the commencement of an anti-TNF agent where possible.^{9,11,14,19,97} When this is not possible, guidelines vary in terms of the duration of anti-tuberculous therapy required prior to commencing anti-TNF but the majority recommend completing between 1 and 2 months despite the lack of clinical evidence justifying these time frames.^{37,40} ECCO guidelines recommend delaying anti-TNF therapy until 3 weeks of antituberculosis therapy has been completed,¹¹ ACG clinical guidelines recommend 'several weeks or months'⁹⁷ and

WHO guidelines do not specify details on timing.⁹ In cases of greater clinical urgency, accepted earlier institution of immunosuppressive agents is advised, but only once active TB has been adequately excluded.

In patients requiring urgent anti-TNF therapy, infectious diseases consultation is recommended where possible. Additionally, although there are no IBD-specific data on this, indirect evidence suggests that a strategy of concomitant commencement of LTBI therapy and severe immunosuppression is safe. For example, in patients undergoing bone marrow and solid organ transplantation who simultaneously start LTBI and immunosuppressive therapy, TB reactivation risk is very low.⁹⁸⁻¹⁰⁰

Importantly, the implementation of guidelines to identify and empirically treat LTBI in anti-TNF exposed patients has demonstrated efficacy.¹⁰¹ Published data extracted from the BIOBADASER (Spanish Society of Rheumatology Database on Biological Products) cohort showed an impressive reduction in rates of active TB when comparing pre- and post-implementation of LTBI treatment guidelines (IRR 0.22, 95% CI 0.03-0.88; $p = 0.008$).¹⁰¹ Extrapolation of such findings to the IBD population seems entirely reasonable.

There does not appear to be any interaction between anti-TNF therapies and anti-mycobacterial treatment.

6.5 | Anti-integrin

Vedolizumab is a humanised anti- $\alpha_4\beta_7$ integrin monoclonal antibody recommended for induction and maintenance of moderately to severely active IBD in patients who are refractory to first-line therapies.¹⁰²⁻¹⁰⁴ The $\alpha_4\beta_7$ integrin binds mucosal addressing cell adhesion molecule-1 expressed on mucosal endothelial cells to facilitate the homing of gastrointestinal T-lymphocytes, which is inhibited by the integrin antagonist.¹⁰⁵ Vedolizumab has minimal systemic toxicity owing to its gastrointestinal tract selective mode of action.^{105,106}

Initial randomised controlled trials demonstrated favourable safety profiles in the short term, particularly in relation to the risk of serious and opportunistic infections.^{102,103} However, there may be a small increase in the risk of gastrointestinal infections.¹⁰⁷ Larger phase 4 cohorts including post-marketing surveillance confirm a low incidence of serious infections in the long term with vedolizumab.¹⁰⁸ Pooled data from 2830 patients treated with vedolizumab from six randomised controlled trials identified only four cases of TB. However, patients with LTBI were excluded from screening.^{104,107} These cases were, therefore, considered likely or possible primary infections, as they had negative screening tests on study entry. Importantly, all these patients were on concomitant immunosuppressive therapy.

There are no current guidelines available advising management of LTBI in patients requiring or receiving vedolizumab. While its gut-selective actions might theoretically reduce the risk of reactivation, there is a paucity of information about the use of vedolizumab in such patients. Likewise, there is no evidence guiding the timing of

concomitant LTBI therapy and vedolizumab therapy, and an ongoing review of the literature in this area is required.

There does not appear to be any interaction between vedolizumab and anti-mycobacterial therapies.

6.6 | Anti-IL-12/23

Ustekinumab is a humanised anti-p40 monoclonal antibody recommended for inducing and maintaining remission in patients with moderate to severe IBD.¹⁰⁹ P40 is a protein subunit shared by two cytokines, IL-12 and IL-23. IL-12 and IL-23 are important in the host defence against intracellular pathogens including *Mycobacteria*.^{110,111} Thus, theoretically, the risk of reactivation of TB is similar to that of anti-TNF therapy.

Despite this theoretical concern, there was only one case of TB in the Crohn's disease registration (UNITI) trials for ustekinumab, and this occurred 10 months after the administration of a single dose of 130 mg of ustekinumab intravenously.¹⁰⁹ There are case reports describing TB reactivation in patients on ustekinumab, but only in patients not receiving concomitant anti-tuberculosis therapy.¹¹² Safety data of 3177 psoriasis patients integrated from five randomised controlled trials included patients with LTBI if treatment was initiated before or at the same time as the first administration of the study drug. No cases of LTBI reactivation occurred in patients who received isoniazid treatment prior to, or concomitantly with, initiation of ustekinumab.^{113,114} There are no current guidelines or real-world data available guiding the management of LTBI in patients requiring or receiving ustekinumab, so due to a lack of adequate data, recommendations follow those for anti-TNF agents. Thus, completion of latent TB treatment prior to commencement of ustekinumab is ideal where possible or ustekinumab initiation should be delayed in order to complete at least 3 weeks of anti-tuberculosis treatment. However, this window can be shortened when clinically necessary, although infectious diseases consultation is recommended.

There does not appear to be any interaction between anti-IL-12/23 agents and anti-mycobacterial therapies.

6.7 | Janus kinase inhibitors

This family of orally administered targeted small molecules selectively inhibit interleukin-mediated intracellular signal transmission. Tofacitinib is the first agent available in this class and it is indicated as an induction and maintenance therapy in UC.¹¹⁵⁻¹¹⁷

Increased overall rates of infection are reported with its use, including a consistently reported increased risk of Herpes zoster infection across trials in UC, CD and RA patients. Although no cases of tuberculosis occurred in the initial IBD induction trials, patients with LTBI were excluded from enrolment.¹¹⁷⁻¹¹⁹ Pooled safety data have been published from two long-term open-label extension studies evaluating tofacitinib at a dose of 5 or 10 mg

twice daily in 6194 patients RA patients up to 8.5 years.¹²⁰ The incidence ratio (IR) for tuberculosis was 0.2 (0.1–0.3), with no notable difference with longer duration exposure. For the statistical analysis, TB rates were stratified by geographical background rates, and 28/36 cases of TB occurred in endemic regions. Out of the 301 rheumatoid arthritis patients with latent TB infection at screening prior to commencing tofacitinib, 23 were considered to be untreated and were, therefore, retreated for 4 weeks prior to study commencement. None of these patients developed active TB.¹²¹

There are no current guidelines or real-world evidence available to guide the management of LTBI in patients requiring or receiving tofacitinib. However, given its systemic action and association with an increased risk of infection,¹²⁰ patients should undergo LTBI screening and treatment if positive prior to initiating tofacitinib. There is no evidence guiding time frames but, as mentioned above, clinical trials required 4 weeks of LTBI treatment before initiation of Janus kinase (JAK)-inhibitor therapy without any cases of reactivation and this seems a reasonable time interval.

Notably, in patients requiring treatment for LTBI who will have concomitant JAK-inhibitor therapy, rifampicin may reduce the serum levels of tofacitinib.¹²² Therefore, the use of a rifampicin-free regimen should be considered.

6.8 | Calcineurin inhibitors

The calcineurin inhibitors (CNI), cyclosporine and tacrolimus, are indicated for inducing remission in moderate to severe steroid-refractory IBD.¹²³⁻¹²⁷ Tacrolimus is also used as maintenance therapy¹²⁸ and in suppository and enema formulation for patients with proctitis.¹²⁹ Tacrolimus has a more favourable pharmacokinetic and side-effect profile compared to cyclosporine. However, according to international guidelines, both these agents should be used only as a bridge to a proposed maintenance therapy agent and discontinued within 6 months due to the risk of side effects.¹³⁰

In post-transplant cohorts, CNI is known to increase the risk of active TB infection.^{131,132} A retrospective study reported a 2.5 times higher ($p = 0.0311$) risk of early post-transplantation TB with cyclosporine therapy compared to patients treated with a combination of corticosteroids and azathioprine.^{133,134} However, patients undergoing bone marrow and solid organ transplantation who simultaneously start LTBI and immunosuppressive therapy have a very low risk of TB reactivation.⁹⁸⁻¹⁰⁰

The risk of CNI-related serious and opportunistic infections in non-transplant settings is lower,^{135,136} which likely reflects dosing and concomitant immunosuppressive agents. The dose range for most rheumatological and dermatological conditions is 2.5–5 mg/kg, which is much lower than the doses used in the transplant setting. In IBD, the initial dose of cyclosporine is 2 mg/kg, which has

been compared directly to 4 mg/kg demonstrating no difference in efficacy.¹³⁷

There are no current guidelines regarding the management of LTBI in IBD patients receiving CNI therapy. However, patients receiving CNI prior to or following solid organ or haematological transplantation are recommended to undergo LTBI screening and treatment. Despite the lower dose used for IBD patients, CNI has systemic immunosuppressive action and therefore LTBI treatment should ideally be completed before initiation of CNI therapy. Where this is greater clinical urgency, as per the recommendations for anti-TNF-based therapies, delaying CNI therapy until at least 3 weeks of anti-tuberculosis treatment would be a reasonable approach.

Notably, in patients requiring treatment for LTBI who will have concomitant CNI therapy, rifampicin may reduce the serum levels of the CNI.¹³⁸ Therefore, the use of a rifampicin-free regimen should be considered.

7 | MONITORING DURING LTBI TREATMENT

Close follow-up during LTBI treatment is essential. Monitoring for adverse effects, including hepatotoxicity and neurotoxicity, is prudent and should be performed according to the individual patient's risk. Patients with risks or cofactors for liver injury, including excessive alcohol consumption (all patients should be counselled to minimise alcohol intake during treatment), female sex, age >65, malnutrition, hepatotoxic medications (such as methotrexate and thiopurines), concomitant viral hepatitis or underlying liver disease, warrant at least monthly liver function tests. This is particularly important with isoniazid, or when baseline liver function tests are abnormal.¹³⁹

Patient education is required on the need for avoidance of alcohol consumption and medications that induce liver injury, and immediate reporting of symptoms should they arise.¹⁴⁰ Symptoms of hepatotoxicity may include fatigue, nausea, right upper quadrant pain, pruritis and jaundice.

Treatment interruption is required, with a modified or alternative regimen instituted, when liver function test derangement meets the following criteria: alanine aminotransferase (ALT) >3× upper limit of normal (ULN) with symptoms or >5× ULN in asymptomatic patients.¹³⁹ Drug-induced liver injury secondary to anti-tuberculous medications can progress to fulminant hepatic failure in approximately 1% of cases, particularly when drug-induced hepatitis is recognised late, reinforcing the need for vigilant monitoring.^{141,142}

Additionally, 'directly observed therapy' can be implemented to ensure adherence to particular regimens such as rifampentine–isoniazid combination therapy. Directly observed therapy involves patients being provided with and observed taking their medications each day. This strategy is used to prevent relapse and the development of

resistance.¹⁴³ Directly observed therapy has been shown to improve the likelihood of completing anti-TB therapy courses but is not warranted in all patients. Rather, this strategy should be considered in individuals with a high risk for non-adherence.^{143,144}

8 | DRUG INTERACTIONS

Anti-mycobacterial agents interact with other medications as well as among themselves (Table 6). Additionally, the use of drug

TABLE 6 Drug-drug interactions and toxicity risk between anti-mycobacterial agents and IBD therapies

	Isoniazid	Rifampicin	Rifapentine Given rifapentine is a moderate CYP3A4 inhibitor, similar effects but to a lesser extent are expected with drugs compared to rifampicin, a strong CYP3A4 inhibitor
5-ASA	○	○	○
Methotrexate	● Hepatotoxicity Both agents have the potential to increase liver function tests. Monitor blood	● Hepatotoxicity	● Hepatotoxicity
Thiopurines	● Hepatotoxicity Both agents have the potential to increase liver function tests. Monitor blood and consider that raised liver enzymes at beginning of isoniazid could be thiopurine related to those patients on thiopurines	○	○
Infliximab	○	○	○
Adalimumab	○	○	○
Golimumab	○	○	○
Vedolizumab	○	○	○
Ustekinumab	○	○	○
Tofacitinib	○	● Tofacitinib is ↓ AUC reduced by about 85% and C _{max} reduced by about 75%. Consider alternative IBD therapy	● Tofacitinib is ↓ Likely to be significant, recommend avoid
Prednisolone	● Isoniazid is ↓	● Prednisolone is ↓ AUC reduced by about 60%, half-life decreased by 40%–60%. ¹⁶⁹ Maximum interaction by day 14. Interaction disappears 14 days after rifampicin withdrawal. ⁶³ Consider increasing prednisolone by two–three-fold	● Prednisolone is ↓
Opioids	○	● Opioids are ↓ Decrease in morphine AUC by 28%, C _{max} by 41%. Decrease in oral and IV oxycodone AUC by 53% and 86%, respectively, and reduced oral bioavailability from 69% to 21%. ^{170,171}	● Opioids ↓
Calcineurin inhibitors	○	● Calcineurin inhibitors are ↓ Tacrolimus and cyclosporine are reduced through the induction of CYP450 with rifampentine. Monitor calcineurin levels carefully	● Calcineurin inhibitors ↓ Reduction of calcineurin levels is less marked with rifapentine compared to rifampicin. However, careful monitoring of calcineurin levels is still recommended

- Nil interactions.
- Consider monitoring and theoretical interaction.
- Interaction expected, dose adjusted as appropriate.

combinations to enhance efficacy and reduce the emergence of resistance, as well as the protracted courses of treatment, increase the likelihood of patients requiring the use of concomitant medications.

9 | LTBI MANAGEMENT REQUIRING IMMEDIATE IMMUNOSUPPRESSION

There are particular circumstances when patients with IBD require immediate commencement of immunosuppressive therapy. First-line therapy during a severe IBD flare is usually institution of high-dose corticosteroid therapy. In patients with acute severe ulcerative colitis inadequately responding to 72h of corticosteroid therapy, guidelines recommend initiation of rescue immunosuppressive therapy with either anti-TNF therapy or cyclosporine.¹⁴⁵ Therefore, patients who have not previously been tested for LTBI or have had possible TB exposure since testing should undergo LTBI screening on admission to expedite results.

There are no data available handling TB-reactivation risk in this specific setting in patients with LTBI. However, there is some literature evaluating outcomes of other cohorts of patients needing urgent immunosuppressive therapy who are simultaneously diagnosed with latent or active TB, including patients undergoing bone marrow and solid organ transplantation. The evidence overall supports the simultaneous commencement of active and LTBI therapy with immunosuppressive therapy.⁹⁸⁻¹⁰⁰ However, collaborative specialist physician-driven management for both IBD and TB is required in these settings.

Other complicating factors to carefully consider are the drug interactions that exist between rifampicin and rescue immunosuppressive medications. Rifampicin lowers the drug concentrations of calcineurin inhibitors (cyclosporine and tacrolimus) and corticosteroids. A combination of immunosuppressive and anti-TB therapy also increases the risk of adverse drug events. Alternatives, such as the use of rifabutin, may be considered given the lesser degree of interaction with immunosuppressive medications.

In the event that a patient requires urgent immunosuppression and LTBI screening for is positive or indeterminate, referral to an infectious disease physician is essential. These complex clinical scenarios require multidisciplinary teams to carefully consider each individual case.

10 | MANAGEMENT OF IBD IN TB-ENDEMIC COUNTRIES

The approach to the investigation and management of LTBI in IBD patients is similar between TB-endemic and non-endemic countries. However, the prevalence of LTBI in these countries is evidently higher, and thus injudicious anti-TNF use may pose a serious health risk.

Due to the high prevalence of tuberculosis in these countries, chest radiographs combined with the TST or IGRA may be insufficient to screen for tuberculosis.⁴⁸ Therefore, chest computer tomography

has sometimes been recommended as an adjunctive to IGRA before commencing immunosuppressive therapies,^{146,147} including prior to biological agents and small molecule inhibitors, in high-prevalence regions.⁴⁶ Supporting this, a recent study from India demonstrated that stringent screening for LTBI prior to anti-TNF therapy that includes clinical history, TST, LTBI, CXR and CT chest can significantly mitigate the risk of TB reactivation.⁵⁰ In this study by Kumar et al,⁵⁰ 112 patients were screened between January 2005 and January 2019 with a less stringent regimen of clinical history and TST plus or minus an IGRA, CXR and/or CT chest at the discretion of the treating physician. Their outcomes were compared to 59 patients screened after January 2019 with the stringent screening strategy. Patients were commenced on chemoprophylaxis if any of the tests were positive. On the follow-up, 17% developed TB in the earlier less stringent screening group compared to only 1.7% in the later stringent screening cohort, suggesting the benefit of complete screening that includes CT chest in patients from high risk, endemic areas. Increasing the diagnostic yield of testing is considered particularly important in more urgent settings such as acute severe ulcerative colitis, during which the cost and risk of radiation is outweighed by the need to identify and treat cases of LTBI. However, clinical practice varies significantly as this remains an almost evidence-free zone.

Furthermore, patients with negative baseline LTBI tests on immunosuppressive therapy who have an ongoing high risk of TB exposure may be considered for repeat testing, although there is limited evidence to guide recommendations.

Finally, the management of IBD in TB-endemic countries should follow the same principles as in non-TB-endemic countries. However, when selecting immunosuppressive therapies, the ongoing risk of TB infection should be taken into account. Where there is equivalent efficacy, non-anti-TNF therapies may be chosen as the first-line biological therapy.

11 | SURVEILLANCE OF LTBI DURING IMMUNOSUPPRESSION

Existing guidelines vary in terms of ongoing surveillance for exposure to, and acquiring, TB infection during immunosuppression.^{33,37,40,43,148} It is recommended that clinicians should take a clinical history and perform a respiratory examination at each review. However, this is not consistent with clinical practice nor is it always possible as fewer face-to-face appointments are being conducted with the increasing use of telehealth in the COVID-19 era. Routine laboratory or imaging surveillance is not recommended but should be considered if a patient reports a new exposure.

A prospective trial over 3 years demonstrated that IGRA conversion commonly occurred in areas with intermediate TB burden and that IGRA levels higher than 4.00 IU/ml were independently associated with the development of active TB (incidence rate ratio 42.2, 95% CI 17.2–99.7, $p < 0.001$).¹⁴⁹ This study suggests the potential role of serial IGRAs during immunosuppressive therapy, supporting

the guidelines that advise annual TB screening.^{33,40,148} However, this recommendation is not universally purported.^{37,43}

12 | REPEAT TESTING FOR PATIENTS TRAVELLING TO ENDEMIC COUNTRIES

A recent global survey of 305 IBD physicians assessed clinicians' management strategies for patients on immunosuppressive therapies visiting TB-endemic areas. Great variability in practice was demonstrated. This may reflect the absence of current guidelines on how to approach the management of these patients prior to and during their travel.¹⁵⁰

There are three phases of travel risk assessment during which travel medicine practitioners may institute risk-reducing measures, defined as pre-travel, during travel and post-travel.

12.1 | Pre-travel

Pre-travel risk assessment consists of a thorough history exploring the likelihood of TB exposure and ascertaining the relative susceptibility of the individual. Countries being visited and the length and location of stay should be evaluated according to the background incidence of TB, as well as multi-drug-resistant TB, in the region. Recreational and work activities may expose additional occupational hazards such as for healthcare workers. As previously mentioned, those at higher risk include patients visiting friends and relatives, children less than 5 years old, immunocompromised individuals (HIV infection, anti-TNF and corticosteroid therapy), cigarette smokers and patients with chronic kidney disease.¹⁵¹

For persons at high risk of exposure or those who are at greater risk of developing active TB following initial infection, testing with LTBI should be initiated prior to travel with either IGRA or TST. A baseline negative test is useful for comparison post-exposure. If a person is found to have LTBI, then consideration of treatment should be made on a case-by-case basis. The presently available BCG vaccination has an approximated efficacy of only 50%. Routine practice includes vaccinating high-risk persons travelling to high-prevalence countries for over 1 month including children younger than 5 years old and healthcare workers. Unfortunately, BCG is contraindicated in the setting of immunodeficiency/immunosuppression.¹⁵²

12.2 | During travel

Risk reduction interventions should be recommended to travellers who will be in prolonged contact with people infected with TB, particularly those working or living in confined spaces. This has been addressed in previous publications.¹⁵³ Personal protective wear such as appropriately ventilated masks can be taken. Alternatively, seeking guidance from local practitioners regarding the availability of personal protective equipment should be encouraged.

12.3 | Post-travel

In a returned traveller, the post-travel assessment should focus on identifying signs and symptoms suggestive of active TB. If there is any suspicion of a pulmonary tuberculous infection, the patient should immediately be referred for expert evaluation. For asymptomatic persons with a known or high likelihood of exposure, assessment for LTBI is recommended with either IGRA or TST, usually 8–10 weeks after return. Although delayed testing may increase the risk of missing early seroconverts and those who fail to attend, this represents the time at which the result becomes more reliably positive.¹⁵⁴ In the setting of recent exposure and conversion from a negative to a positive test for LTBI, treatment should be considered, as the risk of progression to active disease is most significant in the first few years post-exposure.¹⁵³

13 | SURVEILLANCE OF PATIENTS PREVIOUSLY TREATED FOR LTBI

Cure rates with completed therapy are as high as 90% depending on the regimen and duration of therapy. However, protracted courses reduce adherence rates, which can increase the risk of reactivation, supported by increased relapse rates that occur with therapy duration reduction.¹⁵⁵ However, it is very much dependent on the regimen used as randomised controlled trials evaluating a shortened fluoroquinolone containing regimen to 4 months was non-inferior to 6 months.^{156,157} Therefore, early discontinuation of some regimens may not impact relapse rates.

Unfortunately, there are no clinical tests available for assessing the risk of relapse or to identify re-exposure in patients who have previously been treated for LTBI given that IGRA and TST do not reliably become negative and frequently remain positive long term after treatment. It is imperative that patients who have previously been exposed and/or treated are educated about their risk of recurrent infection to avoid further exposure where possible. In the setting of incomplete treatment or likely re-exposure, such as in a returned traveller from an endemic country, clinical history, physical examination and imaging with either a chest X-ray or a CT scan must be performed with clinicians maintaining a low threshold for active disease.

14 | GAPS IN EVIDENCE

The literature is limited with regard to LTBI screening, diagnosis and treatment indications in the IBD population. There are no clinical trials evaluating the timing of LTBI therapy in relation to the use of immunosuppressive therapies or duration of anti-TB therapy, resulting in guidelines that have major methodological gaps in their recommendations for this cohort. Additionally, the risk of exposure and acquisition of LTBI in IBD patients following travel or migration to high-prevalence countries is not well characterised in the literature.

As such, the capacity to develop evidence-based guidelines to advise these patients, as well as to screen and treat them, is limited.

15 | CONCLUSION

TB infection is of paramount relevance to the IBD population given the increasing likelihood of immunosuppression. Therefore, proactive screening in all patients with IBD is recommended.^{11,14} Summarised is a suggested approach to screening, diagnosis and management of LTBI in the setting of IBD and the frequently used medications. Ongoing surveillance for LTBI is advised in patients with IBD throughout the course of their disease, particularly following travel to endemic countries, high-risk exposures and in the context of drug therapy escalation. Active collaboration with infectious diseases clinicians, especially in complex cases such as those requiring emergent immunosuppression, is imperative. There remain major gaps in evidence in many situations, particularly in association with specific newer therapeutic approaches. Reporting of real-world experience will be important in changing current recommendations that aim to mitigate the detrimental effects of LTBI on achieving IBD control and vice versa.

ACKNOWLEDGEMENTS

Ralley Prentice contributed to some grammatical edits to the study. Eva Zhang is supported by a Pfizer Grant to support her fellowship. Aysha H. Al-Ani is supported by an Australian Commonwealth Government Research grant, a Crohn's Colitis Foundation scholarship and a University of Melbourne Scholarship. Sasha Fehily is supported by an NHMRC scholarship to support her fellowship, and has received Pfizer funding contribution towards a conference attendance. All authors approved the final version of the manuscript.

Declaration of personal interests: CR: Has served as a speaker for Pfizer. DJ: Douglas Johnson has served as a speaker for Pfizer. He is an employee of the Royal Melbourne Hospital and has no other conflicts of interest or declarations. SN has received research grants from Ferring and Abbvie and speakers honorarium from Janssen, Abbvie, Tillotts, Takeda, Olympus and Ferring. DR reports grants and personal fees from Abbvie, personal fees from Abgenomics, personal fees from Allergan Inc, personal fees from Boehringer Ingelheim Ltd, personal fees from Bristol-Myers Squibb, personal fees from Celgene Corp/Syneos, personal fees from Check-cap, personal fees from Dizal Pharmaceuticals, personal fees from GalenPharma/Atlantica, grants and personal fees from Genentech/Roche, personal fees from Gilead Sciences, personal fees from Ichnos Sciences, personal fees from GlaxoSmithKline Group, grants and personal fees from Janssen Pharmaceuticals, personal fees from Lilly, personal fees from Narrow River Mgmt, personal fees from Pfizer, grants and personal fees from Prometheus Laboratories, personal fees from Reistone, grants and personal fees from Shire, grants and personal fees from Takeda, personal fees from Techlab, Inc, outside the submitted work. Professor Gibson has served as a consultant or advisory board member for Anata, Atmo Biosciences, Immunic Therapeutics, Novozymes, Novoviah and Comvita. He has received research grants for

investigator-driven studies from Atmo Biosciences. He holds shares in Atmo Biosciences. His Department financially benefits from the sales of a digital application, booklets and online courses on the FODMAP diet. BC has received speaking fees from Abbvie, Janssen, Pfizer, Takeda, Falk Pharmaceuticals, Chiesi and Ferring, research grants from Janssen and Ferring Pharmaceuticals and served on the advisory board of Gilead, Janssen, Celltrion, Abbvie and Novartis

Personal and funding interests: SF has received an education grant from Pfizer. AA is funded by scholarships from Crohn's and Colitis Australia, Avant, the Australian Commonwealth Government and University of Melbourne and received grants from the Gastroenterological Society of Australia/Celltrion Healthcare and Janssen.

AUTHOR CONTRIBUTIONS

Sasha Rachel Fehily: Conceptualization (equal); data curation (equal); writing – original draft (equal); writing – review and editing (equal). **Aysha H. Al-Ani:** Data curation (equal); writing – original draft (equal); writing – review and editing (equal). **Eva Zhang:** Data curation (equal); writing – review and editing (equal). **Jonathan Abdelmalak:** Data curation (equal); writing – original draft (equal). **Clarissa Rentsch:** Data curation (equal); writing – original draft (equal); writing – review and editing (equal). **Douglas F. Johnson:** Conceptualization (equal); data curation (equal); supervision (equal); writing – review and editing (equal). **Justin Denholm:** Conceptualization (equal); data curation (equal); supervision (equal); writing – original draft (equal); writing – review and editing (equal). **Siew C Ng:** Data curation (equal); supervision (equal); writing – review and editing (equal). **David T. Rubin:** Data curation (equal); supervision (equal); writing – review and editing (equal). **Vishal Sharma:** Data curation (equal); supervision (equal); writing – review and editing (equal). **Peter Gibson:** Data curation (equal); supervision (equal); writing – review and editing (equal). **Britt Christensen:** Conceptualization (equal); data curation (equal); supervision (equal); writing – review and editing (equal).

AUTHORSHIP

Guarantor of the article: Britt Christensen.

DATA AVAILABILITY STATEMENT

Not available

ORCID

Sasha R. Fehily  <https://orcid.org/0000-0001-5344-2548>

Aysha H. Al-Ani  <https://orcid.org/0000-0002-4735-5234>

Jonathan Abdelmalak  <https://orcid.org/0000-0001-7550-8202>

Siew C. Ng  <https://orcid.org/0000-0002-6850-4454>

Vishal Sharma  <https://orcid.org/0000-0003-2472-3409>

David T. Rubin  <https://orcid.org/0000-0001-5647-1723>

Britt Christensen  <https://orcid.org/0000-0002-8746-4275>

REFERENCES

1. World health organisation. Global tuberculosis report. Geneva: World Health Organisation; 2021. [cited 2002 May 17]. Available

- from: <https://www.who.int/publications/digital/global-tuberculosis-report-2021/tb-disease-burden/incidence>
2. Rao M and 7 others. Latent TB infection (LTBI) - mycobacterium tuberculosis pathogenesis and the dynamics of the granuloma battleground. *Int J Infect Dis.* 2019;80S:S58–61.
 3. Menzies NA, Cohen T, Salomon JA. Evidence sources on the natural history of latent tuberculosis infection. *Lancet Infect Dis.* 2018;18(8):834–5.
 4. Houben RM, Dodd PJ. The global Burden of latent tuberculosis infection: a re-estimation using mathematical modelling. *PLoS Med.* 2016;13(10):e1002152.
 5. Trauer JM and 6 others. Risk of active tuberculosis in the five years following infection... 15%? *Chest.* 2016;149(2):516–25.
 6. Mir Viladrich I and 6 others. Consensus document on prevention and treatment of tuberculosis in patients for biological treatment. *Arch Bronconeumol.* 2016;52(1):36–45.
 7. Bastian I, Shephard L, Lumb R. Revised guidelines for Australian laboratories performing mycobacteriology testing. *Commun Dis Intellig.* 2021;44. <http://dx.doi.org/10.33321/cdi.2020.44.2>
 8. World Health Organisation. Latent TB Infection: Updated and consolidated guidelines for programmatic management. Geneva: WHO; 2018. Report No.: WHO/CDS/TB/2018.4.
 9. World Health Organization. Latent tuberculosis infection: updated and consolidated guidelines for programmatic management. 2018.
 10. Lorenzetti R and 6 others. Higher risk of tuberculosis reactivation when anti-TNF is combined with immunosuppressive agents: a systematic review of randomized controlled trials. *Ann Med.* 2014;46(7):547–54.
 11. Rahier J-F and 22 others, European Crohn's and Colitis Organisation (ECCO). Second European evidence-based consensus on the prevention, diagnosis and management of opportunistic infections in inflammatory bowel disease. *J Crohn's Colitis.* 2014;8(6):443–68.
 12. Australian Government Department of Health. Coronavirus (COVID-19) health alert 2020 [updated 25 March 2020. Available from: https://www.health.gov.au/news/health-alerts/novel-coronavirus-2019-ncov-health-alert?utm_source=health.gov.au&utm_medium=redirect&utm_campaign=digital_transformation&utm_content=health-topics/novel-coronavirus-2019-ncov.
 13. Australian Government Department of Health. National position statement for the management of latent tuberculosis infection. Australian Government Department of Health. Available from: <http://www.health.gov.au/internet/main/publishing.nsf/Content/cdi4103-d>.
 14. Lichtenstein GR, Loftus EV, Isaacs KL, Regueiro MD, Gerson LB, Sands BE. ACG clinical guideline: Management of Crohn's disease in adults. *Am J Gastroenterol.* 2018;113(4):481–517.
 15. Papay P and 9 others. Factors impacting the results of interferon-gamma release assay and tuberculin skin test in routine screening for latent tuberculosis in patients with inflammatory bowel diseases. *Inflamm Bowel Dis.* 2011;17(1):84–90.
 16. Cekic C and 6 others. Latent tuberculosis screening tests and active tuberculosis infection rates in Turkish inflammatory bowel disease patients under anti-tumor necrosis factor therapy. *Ann Gastroenterol.* 2015;28(2):241–6.
 17. Agarwal S, Das SK, Agarwal GG, Srivastava R. Steroids decrease prevalence of positive tuberculin skin test in rheumatoid Arthritis: implications on anti-TNF therapies. *Interdiscip Perspect Infect Dis* 2014;2014:430134, 1, 5.
 18. Lewinsohn DM and 6 others. Official American Thoracic Society/ Infectious Diseases Society of America/Centers for Disease Control and Prevention clinical practice guidelines: diagnosis of tuberculosis in adults and children. *Clin Infect Dis.* 2017;64(2):111–5.
 19. Society AT. CDC. Targeted tuberculin testing and treatment of latent tuberculosis infection. This official statement of the American Thoracic Society was adopted by the ATS Board of Directors, July 1999. This is a Joint Statement of the American Thoracic Society (ATS) and the Centers for Disease Control and Prevention (CDC). This statement was endorsed by the Council of the Infectious Diseases Society of America.(IDSA), September 1999, and the sections of this statement. *Am J Respir Crit Care Med.* 2000;16:S221–47.
 20. Mazurek GH and 6 others. Updated guidelines for using Interferon Gamma Release Assays to detect Mycobacterium tuberculosis infection - United States, 2010. *MMWR Recomm Rep.* 2010;59(RR-5):1–25.
 21. Lalvani A and 9 others. Enhanced contact tracing and spatial tracking of mycobacterium tuberculosis infection by enumeration of antigen-specific T cells. *Lancet.* 2001;357(9273):2017–21.
 22. Qumsey B, Ananthakrishnan AN, Skaros S, Bonner M, Issa M, Zadornova Y, et al. QuantiFERON TB gold testing for tuberculosis screening in an inflammatory bowel disease cohort in the United States. *Inflamm Bowel Dis* 2011;17(1):77–83.
 23. Brown J and 9 others. Frequency and significance of indeterminate and borderline quantiferon gold TB IGRA results. *Eur Respir J.* 2017;50(4):1701267.
 24. Vortia E and 7 others. Low indeterminate rates associated with use of the QuantiFERON-TB gold in-tube test in children with inflammatory bowel disease on long-term infliximab. *Inflamm Bowel Dis.* 2018;24(4):877–82.
 25. Hakimian S, Popov Y, Rupawala A, Salomon-Escoto K, Hatch S, Pellish R The conundrum of indeterminate QuantiFERON-TB Gold results before anti-tumor necrosis factor initiation. *Biol Targets Ther.* 2018;12:61–67. <http://dx.doi.org/10.2147/btt.s150958>
 26. van Zyl-Smit RN, Zwerling A, Dheda K, Pai M. Within-subject variability of interferon-gamma assay results for tuberculosis and boosting effect of tuberculin skin testing: a systematic review. *PLoS ONE.* 2009;4(12):e8517.
 27. Corbett EL and 11 others. Provider-initiated symptom screening for tuberculosis in Zimbabwe: diagnostic value and the effect of HIV status. *Bull World Health Organ.* 2010;88(1):13–21.
 28. Ayles H and 6 others. Prevalence of tuberculosis, HIV and respiratory symptoms in two Zambian communities: implications for tuberculosis control in the era of HIV. *PLoS ONE.* 2009;4(5):e5602.
 29. Datta M and 7 others. Survey for tuberculosis in a tribal population in North Arcot District. *Int J Tuberc Lung Dis.* 2001;5(3):240–9.
 30. Gopi PG and 7 others. A baseline survey of the prevalence of tuberculosis in a community in South India at the commencement of a DOTS programme. *Int J Tuberc Lung Dis.* 2003;7(12):1154–62.
 31. Amanullah F and 7 others. High tuberculosis prevalence in children exposed at home to drug-resistant tuberculosis. *Int J Tuberc Lung Dis.* 2014;18(5):520–7.
 32. Shahidi N, Fu YT, Qian H, Bressler B. Performance of interferon-gamma release assays in patients with inflammatory bowel disease: a systematic review and meta-analysis. *Inflamm Bowel Dis.* 2012;18(11):2034–42.
 33. Doherty SD, Van Voorhees A, Lebowitz MG, Korman NJ, Young MS, Hsu S. National Psoriasis Foundation consensus statement on screening for latent tuberculosis infection in patients with psoriasis treated with systemic and biologic agents. *J Am Acad Dermatol.* 2008;59(2):209–17.
 34. Kavanagh PM, Gilmartin JJ, O'Donnell J, O'Flanagan D. Tumour necrosis factor-alpha and tuberculosis: guidance from the national TB advisory Committee. *Ir Med J.* 2008;101(1):6–7.
 35. Fonseca JE and 6 others. Recommendations for the diagnosis and treatment of latent and active tuberculosis in inflammatory joint diseases candidates for therapy with tumor necrosis factor alpha inhibitors - March 2008 update. *Rev Port Pneumol.* 2008;14(2):271–83.
 36. Koike R, Takeuchi T, Eguchi K, Miyasaka N. Japan College of R. update on the Japanese guidelines for the use of

- infliximab and etanercept in rheumatoid arthritis. *Mod Rheumatol*. 2007;17(6):451–8.
37. Mok CC, Tam LS, Chan TH, Lee GK, Li EK. Management of rheumatoid arthritis: consensus recommendations from the Hong Kong Society of Rheumatology. *Clin Rheumatol*. 2011;30(3):303–12.
 38. British Thoracic Society standards of care C. BTS recommendations for assessing risk and for managing mycobacterium tuberculosis infection and disease in patients due to start anti-TNF-alpha treatment. *Thorax*. 2005;60(10):800–5.
 39. Beglinger C and 6 others. Screening for tuberculosis infection before the initiation of an anti-TNF-alpha therapy. *Swiss Med Wkly*. 2007;137(43–44):620–2.
 40. Nordgaard-Lassen I and 6 others. Guidelines for screening, prophylaxis and critical information prior to initiating anti-TNF-alpha treatment. *Dan Med J*. 2012;59(C4480):2011.
 41. Smith CH and 6 others. British Association of Dermatologists' guidelines for biologic interventions for psoriasis 2009. *Br J Dermatol*. 2009;161(5):987–1019.
 42. Hodkinson B, Van Duuren E, Pettipher C, Kalla A, South African R, Arthritis A. South African recommendations for the management of rheumatoid arthritis: an algorithm for the standard of care in 2013. *S Afr Med J*. 2013;103(8 Pt 2):576–85.
 43. Cantini F and 10 others, SAFEBIO (Italian Multidisciplinary Task Force for Screening of Tuberculosis Before and During Biologic Therapy). Guidance for the management of patients with latent tuberculosis infection requiring biologic therapy in rheumatology and dermatology clinical practice. *Autoimmun Rev*. 2015;14(6):503–9.
 44. Duarte R and 7 others. Position paper on tuberculosis screening in patients with immune mediated inflammatory diseases candidates for biological therapy. *Acta Reumatol Port*. 2012;37(3):253–9.
 45. Keith PJ, Wetter DA, Wilson JW, Lehman JS. Evidence-based guidelines for laboratory screening for infectious diseases before initiation of systemic immunosuppressive agents in patients with autoimmune bullous dermatoses. *Br J Dermatol*. 2014;171(6):1307–17.
 46. Ran Z and 20 others. Asian Organization for Crohn's and colitis and Asia Pacific Association of Gastroenterology practice recommendations for medical management and monitoring of inflammatory bowel disease in Asia. *J Gastroenterol Hepatol*. 2020;36:637–45.
 47. Fujikawa A and 9 others. Tuberculosis contact investigation using interferon-gamma release assay with chest x-ray and computed tomography. *PLoS ONE*. 2014;9(1):e85612.
 48. Piccasso R, Paparo F, Garlaschi G. Diagnostic accuracy of chest radiography for the diagnosis of tuberculosis (TB) and its role in the detection of latent TB infection: a systematic review. *J Rheumatol Suppl*. 2014;91:32–40.
 49. Song DJ and 7 others. Tuberculosis screening using IGRA and chest computed tomography in patients with inflammatory bowel disease: a retrospective study. *J Dig Dis*. 2017;18(1):23–30.
 50. Kumar P, Vuyyuru SK, Kante B, Sahu P, Goyal S, Madhu D et al. Stringent screening strategy significantly reduces reactivation rates of tuberculosis in patients with inflammatory bowel disease on anti-TNF therapy in tuberculosis endemic region therapy in tuberculosis endemic region. *Aliment Pharmacol Ther*. 2022;55(11):1431–1440. <http://dx.doi.org/10.1111/apt.16839>
 51. Madhi SA and 8 others, P1041 Study Team. Primary isoniazid prophylaxis against tuberculosis in HIV-exposed children. *N Engl J Med*. 2011;365(1):21–31.
 52. Collins P, Rhodes J. Ulcerative colitis: diagnosis and management. *BMJ*. 2006;333(7563):340–3.
 53. Moss AC, Peppercorn MA. The risks and the benefits of mesalazine as a treatment for ulcerative colitis. *Expert Opin Drug Saf*. 2007;6(2):99–107.
 54. Ransford R, Langman M. Sulphasalazine and mesalazine: serious adverse reactions re-evaluated on the basis of suspected adverse reaction reports to the Committee on safety of medicines. *Gut*. 2002;51(4):536–9.
 55. Keisu M, Ekman E. Sulfasalazine associated agranulocytosis in Sweden 1972–1989. *Eur J Clin Pharmacol*. 1992;43(3):215–8.
 56. Balow JE, Rosenthal AS. Glucocorticoid suppression of macrophage migration inhibitory factor. *J Exp Med*. 1973;137(4):1031–41.
 57. Rinehart JJ, Sagone AL, Balcerzak SP, Ackerman GA, LoBuglio AF. Effects of corticosteroid therapy on human monocyte function. *N Engl J Med*. 1975;292(5):236–41.
 58. Ford AC and 6 others. Glucocorticosteroid therapy in inflammatory bowel disease: systematic review and meta-analysis. *Am J Gastroenterol*. 2011;106(4):590–9.
 59. Jick SS, Lieberman ES, Rahman MU, Choi HK. Glucocorticoid use, other associated factors, and the risk of tuberculosis. *Arthritis Care Res*. 2006;55(1):19–26.
 60. Lichtenstein GR and 7 others. Serious infections and mortality in association with therapies for Crohn's disease: TREAT registry. *Clin Gastroenterol Hepatol*. 2006;4(5):621–30.
 61. Weng M-T and 6 others. Trends of medication usage and associated outcomes for Taiwanese patients with inflammatory bowel disease from 2001 to 2015. *J Clin Med*. 2018;7(11):394.
 62. Long W, Cai F, Wang X, Zheng N, Wu R. High risk of activation of latent tuberculosis infection in rheumatic disease patients. *Infect Dis (Lond)*. 2020;52(2):80–6.
 63. Bergrem H, Refvem OK. Altered prednisolone pharmacokinetics in patients treated with rifampicin. *Acta Med Scand*. 1983;213(5):339–43.
 64. Pettit A. Mechanism of action of purine analogues in chronic lymphocytic leukemia. *Br J Haematol*. 2003;121:692–702.
 65. Vermeire S, Van Assche G & Rutgeerts P. Therapy: purine analogs and methotrexate. In: Bernstein C, editor. *The inflammatory bowel disease yearbook*. New York: REMEDICA; 2006. Vol. 3. p. 91.
 66. Timmer A, Patton PH, Chande N, McDonald JWD, MacDonald JK. Azathioprine and 6-mercaptopurine for maintenance of remission in ulcerative colitis. *Cochrane Database Syst Rev*. 2016;2016(5). <http://dx.doi.org/10.1002/14651858.cd000478.pub4>
 67. Jackson B, De Cruz P. Algorithms to facilitate shared decision-making for the management of mild-to-moderate ulcerative colitis. *Expert Rev Gastroenterol Hepatol*. 2018;12(11):1079–100.
 68. Colombel JF and 12 others. Infliximab, azathioprine, or combination therapy for Crohn's disease. *N Engl J Med*. 2010;362(15):1383–95.
 69. Panaccione R, Ghosh S, Middleton S, Márquez JR, Scott BB, Flint L, et al. Combination therapy with infliximab and azathioprine is superior to monotherapy with either agent in ulcerative colitis. *Gastroenterology* 2014;146(2):392–400. e3, 400.e3.
 70. Lennard L, Van Loon JA, Lillieyman JS, Weinsilbom RM. Thiopurine pharmacogenetics in leukemia: correlation of erythrocyte thiopurine methyltransferase activity and 6-thioguanine nucleotide concentrations. *Clin Pharmacol Therap*. 1987;41(1):18–25.
 71. Deshpande AR, Abreu MT. *Optimizing therapy with 6-mercaptopurine and azathioprine: to measure or not to measure?*. London: Sage Publications Sage UK; 2010.
 72. Seksik P, Cosnes J, Sokol H, Nion-Larmurier I, Gendre JP, Beaugerie L. Incidence of benign upper respiratory tract infections, HSV and HPV cutaneous infections in inflammatory bowel disease patients treated with azathioprine. *Aliment Pharmacol Ther*. 2009;29(10):1106–13.
 73. Shin SJ, Collins MT. Thiopurine drugs azathioprine and 6-mercaptopurine inhibit mycobacterium paratuberculosis growth in vitro. *Antimicrob Agents Chemother*. 2008;52(2):418–26.
 74. Feagan BG and 11 others. A comparison of methotrexate with placebo for the maintenance of remission in Crohn's disease. *N Engl J Med*. 2000;342(22):1627–32.

75. Ardizzone S, Bollani S, Manzionna G, Imbesi V, Colombo E, Porro GB. Comparison between methotrexate and azathioprine in the treatment of chronic active Crohn's disease: a randomised, investigator-blind study. *Dig Liver Dis.* 2003;35(9):619–27.
76. Arora S and 6 others. Methotrexate in Crohn's disease: results of a randomized, double-blind, placebo-controlled trial. *Hepato-Gastroenterology.* 1999;46(27):1724–9.
77. Warren R and 6 others. British Association of Dermatologists' guidelines for the safe and effective prescribing of methotrexate for skin disease 2016. *Brit J Dermatol.* 2016;175(1):23–44.
78. Salliot C, van der Heijde D. Long-term safety of methotrexate monotherapy in patients with rheumatoid arthritis: a systematic literature research. *Ann Rheum Dis.* 2009;68(7):1100–4.
79. Tostmann A, Boeree MJ, Aarnoutse RE, De Lange WC, Van Der Ven AJ, Dekhuijzen R. Antituberculosis drug-induced hepatotoxicity: concise up-to-date review. *J Gastroenterol Hepatol.* 2008;23(2):192–202.
80. Bath RK, Brar NK, Forouhar FA, Wu GY. A review of methotrexate-associated hepatotoxicity. *J Dig Dis.* 2014;15(10):517–24.
81. Vanhoof J, Landewe S, Van Wijngaerden E, Geusens P. High incidence of hepatotoxicity of isoniazid treatment for tuberculosis chemoprophylaxis in patients with rheumatoid arthritis treated with methotrexate or sulfasalazine and anti-tumour necrosis factor inhibitors. *Ann Rheum Dis.* 2003;62(12):1241–2.
82. Chen J, Raymond K. Roles of rifampicin in drug-drug interactions: underlying molecular mechanisms involving the nuclear pregnane X receptor. *Ann Clin Microbiol Antimicrob.* 2006;5(1):3.
83. Present DH and 6 others. Infliximab for the treatment of fistulas in patients with Crohn's disease. *N Engl J Med.* 1999;340(18):1398–405.
84. Targan SR and 6 others. A short-term study of chimeric monoclonal antibody cA2 to tumor necrosis factor α for Crohn's disease. *N Engl J Med.* 1997;337(15):1029–36.
85. Rutgeerts P and 13 others. Infliximab for induction and maintenance therapy for ulcerative colitis. *N Engl J Med.* 2005;353(23):2462–76.
86. Sands BE and 17 others. Infliximab maintenance therapy for fistulizing Crohn's disease. *N Engl J Med.* 2004;350(9):876–85.
87. Bouguen G, Siproudhis L, Gizard E, Wallenhorst T, Billioud V, Bretagne JF, et al. Long-term outcome of perianal fistulizing Crohn's disease treated with infliximab. *Clin Gastroenterol Hepatol* 2013;11(8):975–81. e4, 981.e4.
88. Fallahi-Sichani M, El-Kebir M, Marino S, Kirschner DE, Linderman JJ. Multiscale computational modeling reveals a critical role for TNF- α receptor 1 dynamics in tuberculosis granuloma formation. *J Immunol.* 2011;186(6):3472–83.
89. Katikireddi VS, Whittle SL, Hill CL. Tumour necrosis factor inhibitors and risk of serious infection in rheumatoid arthritis. *Int J Rheum Dis.* 2010;13(1):12–26.
90. Carvalho LP, Túlio MA, Rodrigues JP, e Costa TB, Chagas C. Miliary tuberculosis in a Crohn's disease patient: the risk beyond the screening. GE-Portuguese. *J Gastroenterol.* 2018;26:64–9.
91. Dixon W, Watson K, Lunt M, Hyrich K, Silman A, Symmons D. Rates of serious infection, including site-specific and bacterial intracellular infection, in rheumatoid arthritis patients receiving anti-tumour necrosis factor therapy: results from the British Society for Rheumatology biologics register. *Arthritis Rheumatol.* 2006;54(8):2368–76.
92. Sandborn WJ and 6 others. Adalimumab induces and maintains clinical remission in patients with moderate-to-severe ulcerative colitis. *Gastroenterology.* 2012;142(2):257–265.e3.
93. Wallis R, Broder M, Wong J, Hanson M, Beenhouwer D. Granulomatous infectious diseases associated with tumor necrosis factor antagonists. *Clin Infect Dis.* 2004;38(9):1261–5.
94. Winthrop K and 12 others. Mycobacterial diseases and antitumour necrosis factor therapy in USA. *Ann Rheum Dis.* 2013;72(1):37–42.
95. Askling J and 14 others. Risk and case characteristics of tuberculosis in rheumatoid arthritis associated with tumor necrosis factor antagonists in Sweden. *Arthritis Rheum.* 2005;52(7):1986–92.
96. Salt E and 8 others. Risk factors for targeted fungal and mycobacterial infections in patients taking tumor necrosis factor inhibitors. *Arthritis Rheum.* 2016;68(3):597–603.
97. Centers for Disease Control Prevention. Latent Tuberculosis Infection: a Guide for Primary Health Care Providers. Centers for Disease Control and Prevention; 2020. <https://www.cdc.gov/tb/publications/lbti/pdf/LTBIbooklet508.pdf>
98. Salvador NGA and 9 others. Clinical outcomes of tuberculosis in recipients after living donor liver transplantation. *Ann Transplant.* 2018;23:733–43.
99. Habhab WT and 7 others. Management and outcome of latent tuberculosis in living renal transplant donors. *Saudi J Kidney Dis Transpl.* 2019;30(1):151–2.
100. Eom KS and 10 others. Tuberculosis before hematopoietic stem cell transplantation in patients with hematologic diseases: report of a single-center experience. *Transpl Infect Dis.* 2015;17(1):73–9.
101. Carmona L and 7 others, BIOBADASER Group. Effectiveness of recommendations to prevent reactivation of latent tuberculosis infection in patients treated with tumor necrosis factor antagonists. *Arthritis Rheum.* 2005;52(6):1766–72.
102. Feagan BG and 15 others. Vedolizumab as induction and maintenance therapy for ulcerative colitis. *N Engl J Med.* 2013;369(8):699–710.
103. Sandborn WJ and 16 others. Vedolizumab as induction and maintenance therapy for Crohn's disease. *N Engl J Med.* 2013;369(8):711–21.
104. Vermeire S and 6 others. Long-term efficacy of vedolizumab for Crohn's disease. *J Crohns Colitis.* 2017;11(4):412–24.
105. Wyant T, Fedyk E, Abhyankar B. An overview of the mechanism of action of the monoclonal antibody vedolizumab. *J Crohns Colitis.* 2016;10(12):1437–44.
106. Soler D, Chapman T, Yang L-L, Wyant T, Egan R, Fedyk ER. The binding specificity and selective antagonism of vedolizumab, an anti- α 4 β 7 integrin therapeutic antibody in development for inflammatory bowel diseases. *J Pharmacol Exp Ther.* 2009;330(3):864–75.
107. Colombel J-F and 6 others. The safety of vedolizumab for ulcerative colitis and Crohn's disease. *Gut.* 2017;66(5):839–51.
108. Ng SC and 6 others. Low frequency of opportunistic infections in patients receiving Vedolizumab in clinical trials and post-marketing setting. *Inflamm Bowel Dis.* 2018;24(11):2431–41.
109. Feagan BG and 26 others. Ustekinumab as induction and maintenance therapy for Crohn's disease. *N Engl J Med.* 2016;375(20):1946–60.
110. Germann T, Rude E. Interleukin-12. *Int Arch Allergy Immunol.* 1995;108(2):103–12.
111. D'Elia MM, Del Prete G, Amedei A. Targeting IL-23 in human diseases. *Expert Opin Ther Targets.* 2010;14(7):759–74.
112. Errichetti E, Piccirillo A. Latent tuberculosis reactivation in a patient with erythrodermic psoriasis under treatment with ustekinumab and a low dose steroid, despite isoniazid chemoprophylaxis. *Eur J Dermatol.* 2014;24(4):508–9.
113. Papp K and 11 others, PHOENIX 1 Investigators, PHOENIX 2 Investigators, ACCEPT Investigators. Long-term safety of ustekinumab in patients with moderate-to-severe psoriasis: final results from 5 years of follow-up. *Br J Dermatol.* 2013;168(4):844–54.
114. Tsai TF and 8 others, on behalf of the PHOENIX 1, PHOENIX 2, ACCEPT, PEARL, Japanese Ustekinumab Study Groups. The safety of ustekinumab treatment in patients with moderate-to-severe

- psoriasis and latent tuberculosis infection. *Br J Dermatol*. 2012;167(5):1145–52.
115. Sandborn WJ and 6 others. Tofacitinib, an oral Janus kinase inhibitor, in active ulcerative colitis. *N Engl J Med*. 2012;367(7):616–24.
 116. Sandborn WJ and 6 others. Tofacitinib as induction and maintenance therapy for ulcerative colitis. *N Engl J Med*. 2017;376(18):1723–36.
 117. Panés J and 16 others. Tofacitinib for induction and maintenance therapy of Crohn's disease: results of two phase IIb randomised placebo-controlled trials. *Gut*. 2017;66(6):1049–59.
 118. Wollenhaupt J and 13 others. Safety and efficacy of tofacitinib, an oral janus kinase inhibitor, for the treatment of rheumatoid arthritis in open-label, longterm extension studies. *J Rheumatol*. 2014;41(5):837–52.
 119. Sandborn WJ and 6 others. Efficacy and safety of oral tofacitinib as maintenance therapy in patients with moderate to severe ulcerative colitis: results from a phase 3 randomised controlled trial. *J Crohns Colitis*. 2017;11(S1):S19–20.
 120. Cohen SB and 14 others. Long-term safety of tofacitinib for the treatment of rheumatoid arthritis up to 8.5 years: integrated analysis of data from the global clinical trials. *Ann Rheum Dis*. 2017;76(7):1253–62.
 121. Fleischmann R and 6 others. Safety and maintenance of response for tofacitinib monotherapy and combination therapy in rheumatoid arthritis: an analysis of pooled data from open-label long-term extension studies. *RMD Open*. 2017;3(2):e000491.
 122. Nam SH and 6 others. Early discontinuation of tofacitinib in patients with rheumatoid arthritis co-treated with rifampin for latent tuberculosis. *Joint Bone Spine*. 2020;87(5):475–9.
 123. Baumgart D, Wiedenmann B, Dignass A. Rescue therapy with tacrolimus is effective in patients with severe and refractory inflammatory bowel disease. *Aliment Pharmacol Ther*. 2003;17(10):1273–81.
 124. Lichtiger S and 7 others. Cyclosporine in severe ulcerative colitis refractory to steroid therapy. *N Engl J Med*. 1994;330(26):1841–5.
 125. Kobayashi T and 11 others. Rapid endoscopic improvement is important for 1-year avoidance of colectomy but not for the long-term prognosis in cyclosporine a treatment for ulcerative colitis. *J Gastroenterol*. 2010;45(11):1129–37.
 126. Ogata H and 6 others. A randomised dose finding study of oral tacrolimus (FK506) therapy in refractory ulcerative colitis. *Gut*. 2006;55(9):1255–62.
 127. Ogata H and 7 others. Double-blind, placebo-controlled trial of oral tacrolimus (FK506) in the management of hospitalized patients with steroid-refractory ulcerative colitis. *Inflamm Bowel Dis*. 2012;18(5):803–8.
 128. Ito A, Iizuka B, Omori T, Nakamura S, Tokushige K. Tacrolimus for remission induction and maintenance therapy in patients with ulcerative colitis: a retrospective evaluation study. *Gastroenterol Res Pract*. 2016;2016:1–6.
 129. Fehily SR, Martin FC, Kamm MA. Simple water-based tacrolimus enemas for refractory proctitis. *JGH Open*. 2020;4(4):561–4.
 130. Harbord M, Eliakim R, Bettenworth D, Karmiris K, Katsanos K, Kopylov U et al. Third European evidence-based consensus on diagnosis and management of ulcerative colitis. Part 2: current management. *J Crohns Colitis*. 2017;11:769–784. <http://dx.doi.org/10.1093/ecco-jcc/jjx009>
 131. Agarwal SK, Bhowmik D, Mahajan S, Bagchi S. Impact of type of calcineurin inhibitor on post-transplant tuberculosis: single-center study from India. *Transpl Infect Dis*. 2017;19(1):e12626.
 132. Oh C-S, Stratta RJ, Fox BC, Sollinger HW, Belzer FO, Maki DG. Increased infections associated with the use of OKT3 for treatment of steroid-resistant rejection in renal transplantation. *Transplantation*. 1988;45(1):68–73.
 133. John GT, Date A, Mathew C, Jeyaseelan L, Jacob C, Shastry J. A time table for infections after renal transplantation in the tropics. *Transplantation*. 1996;61(6):970–2.
 134. John GT, Shankar V, Mukundan U, Thomas PP, Jacob CK. Risk factors for post-transplant tuberculosis. *Kidney Int*. 2001;60(3):1148–53.
 135. Schneeweiss MC, Lourdes P-C, Merola JF. Comparative safety of systemic immunomodulatory medications in adults with atopic dermatitis. *J Am Acad Dermatol*. 2021;85(2):321–329. <http://dx.doi.org/10.1016/j.jaad.2019.05.073>
 136. Marra CA, Esdaile JM, Guh D, Fisher JH, Chalmers A, Anis AH. The effectiveness and toxicity of cyclosporin a in rheumatoid arthritis: longitudinal analysis of a population-based registry. *Arthritis Care Res*. 2001;45(3):240–5.
 137. Van Assche G and 6 others. Randomized, double-blind comparison of 4 mg/kg versus 2 mg/kg intravenous cyclosporine in severe ulcerative colitis. *Gastroenterology*. 2003;125(4):1025–31.
 138. Campana C, Regazzi MB, Buggia I, Molinaro M. Clinically significant drug interactions with cyclosporin an update. *Clin Pharmacokinet*. 1996;30(2):141–79.
 139. Saukkonen JJ and 12 others, ATS (American Thoracic Society) Hepatotoxicity of Antituberculosis Therapy Subcommittee. An official ATS statement: hepatotoxicity of antituberculosis therapy. *Am J Respir Crit Care Med*. 2006;174(8):935–52.
 140. Ramappa V, Aithal GP. Hepatotoxicity related to anti-tuberculosis drugs: mechanisms and management. *J Clin Exp Hepatol*. 2013;3(1):37–49.
 141. Devarbhavi H. Antituberculous drug-induced liver injury: current perspective. *Trop Gastroenterol*. 2011;32(3):167–74.
 142. Shen T and 29 others. Incidence and etiology of drug-induced liver injury in mainland China. *Gastroenterology*. 2019;156(8):2230–41 e11.
 143. Aboltins C, Brown L, Darby J, Denholm J, Flynn M & Unit NCID et al. Management, control and prevention of tuberculosis: Guidelines for health care providers 2016. [cited 2002 May 17]. <https://content.health.vic.gov.au/sites/default/files/migrated/files/collections/policies-and-guidelines/t/tb-guidelines-2015.pdf>
 144. Onwubiko U, Wall K, Sales R-M, Holland DP. Using directly observed therapy (DOT) for latent tuberculosis treatment – a hit or a miss? A propensity score analysis of treatment completion among 274 homeless adults in Fulton County, GA. *PLoS ONE*. 2019;14(6):e0218373-e.
 145. Williams JG and 12 others. Comparison of infliximab and cyclosporin in STeroid resistant ulcerative colitis: pragmatic randomised trial and economic evaluation (CONSTRUCT). *Health Technol Assess*. 2016;20(44):1–320.
 146. Saidenberg-Kermanac'h N and 6 others. Screening for latent tuberculosis in anti-TNF- α candidate patients in a high tuberculosis incidence setting. *Int J Tuberc Lung Dis*. 2012;16(10):1307–14.
 147. Lyu J and 9 others. Chest computed tomography is more likely to show latent tuberculosis foci than simple chest radiography in liver transplant candidates. *Liver Transpl*. 2011;17(8):963–8.
 148. Solovic I and 6 others. The risk of tuberculosis related to tumour necrosis factor antagonist therapies: a TBNET consensus statement. *Eur Respiratory Soc*. 2010;36:1185–206.
 149. Lee CK, Wong SHV, Lui G, Tang W, Tam LS, Ip M, et al. A prospective study to monitor for tuberculosis during anti-tumour necrosis factor therapy in patients with inflammatory bowel disease and immune-mediated inflammatory diseases. *J Crohns Colitis*. 2018;12(8):954–962. <http://dx.doi.org/10.1093/ecco-jcc/jjy057>
 150. Chan W, Shim HH, Ng SC, Crohn's AP, Group CESS, Liu J, et al. A global survey of Gastroenterologists' travel advice to patients with inflammatory bowel disease on immunosuppressive agents and management of those visiting tuberculosis-endemic areas. *J Crohns Colitis*. 2018;12(11):1261–9.

151. Fulford M, Keystone JS. Health risks associated with visiting friends and relatives in developing countries. *Curr Infect Dis Rep.* 2005;7(1):48–53.
152. Rogler G. Inflammatory bowel disease in travelers. *Gastroenterol Hepatol (NY).* 2018;14(6):377–9.
153. Denholm JT, Thevarajan I. Tuberculosis and the traveller: evaluating and reducing risk through travel consultation. *J Travel Med* 2016;23(3):taw008, taw031.
154. Lee SW, Oh DK, Lee SH, Kang HY, Lee CT, Yim JJ. Time interval to conversion of interferon-gamma release assay after exposure to tuberculosis. *Eur Respir J.* 2011;37(6):1447–52.
155. Council STSBMR. Clinical trial of six-month and four-month regimens of chemotherapy in the treatment of pulmonary tuberculosis. *Am Rev Respir Dis.* 1979;119(4):579–85.
156. Gillespie SH and 8 others, REMoxTB Consortium. Four-month moxifloxacin-based regimens for drug-sensitive tuberculosis. *N Engl J Med.* 2014;371(17):1577–87.
157. Jindani A and 22 others, RIFAQUIN Trial Team. High-dose rifapentine with moxifloxacin for pulmonary tuberculosis. *N Engl J Med.* 2014;371:1599–608.
158. Smieja M, Marchetti C, Cook D, Smaill FM. Isoniazid for preventing tuberculosis in non-HIV infected persons. *Cochrane Database Syst Rev* 1999. <http://dx.doi.org/10.1002/14651858.cd001363>
159. Zar HJ and 7 others. Effect of isoniazid prophylaxis on mortality and incidence of tuberculosis in children with HIV: randomised controlled trial. *BMJ.* 2007;334(7585):136.
160. Peloquin CA. Therapeutic drug monitoring in antituberculosis chemotherapy. *Ther Drug Monit.* 1999;21(4):426–7.
161. Sharma SK, Sharma A, Kadiravan T, Tharyan P. Rifamycins (rifampicin, rifabutin and rifapentine) compared to isoniazid for preventing tuberculosis in HIV-negative people at risk of active TB. *Evid-Based Child Health Cochrane Rev J.* 2014;9(1):169–294.
162. Hong Kong Chest Service/Tuberculosis Research Centre MBMRC. A double-blind placebo-controlled clinical trial of three antituberculosis chemoprophylaxis regimens in patients with silicosis in Hong Kong. *Am Rev Respir Dis.* 1992;145(1):36–41.
163. Menzies D, Dion M-J, Rabinovitch B, Mannix S, Brassard P, Schwartzman K. Treatment completion and costs of a randomized trial of rifampin for 4 months versus isoniazid for 9 months. *Am J Respir Crit Care Med.* 2004;170(4):445–9.
164. Esfahani K, Aspler A, Menzies D, Schwartzman K. Potential cost-effectiveness of rifampin vs. isoniazid for latent tuberculosis: implications for future clinical trials. *Int J Tuberc Lung Dis.* 2011;15(10):1340–1346. <http://dx.doi.org/10.5588/ijtld.10.0575>
165. Chan P and 6 others. Latent tuberculosis infection treatment for prison inmates: a randomised controlled trial. *Int J Tuberc Lung Dis.* 2012;16(5):633–8.
166. Sterling TR and 16 others. Three months of rifapentine and isoniazid for latent tuberculosis infection. *N Engl J Med.* 2011;365(23):2155–66.
167. Denholm JT and 6 others. SIRCLE: a randomised controlled cost comparison of self-administered short-course isoniazid and rifapentine for cost-effective latent tuberculosis eradication. *Int Med J.* 2017;47(12):1433–6.
168. Martínez EA and 6 others. Compliance, tolerance and effectiveness of a short chemoprophylaxis regimen for the treatment of tuberculosis. *Med Clin.* 1998;111(11):401–4.
169. McAllister WA, Thompson PJ, Al-Habet SM, Rogers HJ. Rifampicin reduces effectiveness and bioavailability of prednisolone. *Br Med J.* 1983;286(6369):923–5.
170. Bolhuis MS, Panday PN, Pranger AD, Kosterink JG, Alffenaar JW. Pharmacokinetic drug interactions of antimicrobial drugs: a systematic review on oxazolidinones, rifamycines, macrolides, fluoroquinolones, and Beta-lactams. *Pharmaceutics.* 2011;3(4):865–913.
171. Niemi M, Backman JT, Fromm MF, Neuvonen PJ, Kivisto KT. Pharmacokinetic interactions with rifampicin: clinical relevance. *Clin Pharmacokinet.* 2003;42(9):819–50.

How to cite this article: Fehily SR, Al-Ani AH, Abdelmalak J, Rentch C, Zhang E, Denholm JT. et al. Review article: latent tuberculosis in patients with inflammatory bowel diseases receiving immunosuppression—risks, screening, diagnosis and management. *Aliment Pharmacol Ther.* 2022;56:6–27. <https://doi.org/10.1111/apt.16952>